Session of 2016

## HOUSE BILL No. 2614

By Committee on Health and Human Services

2-4

AN ACT concerning the state board of pharmacy; powers, duties and 1 2 functions thereof; amending K.S.A. 65-669, 65-1633, 65-1635, 65-1648, 65-1660 and 65-7007 and K.S.A. 2015 Supp. 65-1626, 65-1627, 3 4 65-1636, 65-1637, 65-1642, 65-1643, 65-1645, 65-1655, 65-1663, 65-1669, 65-1676, 65-2837a and 65-4202 and repealing the existing 5 sections; also repealing K.S.A. 2015 Supp. 65-1637b and 65-1651a. 6 7 8 Be it enacted by the Legislature of the State of Kansas: 9 Section 1. K.S.A. 2015 Supp. 65-1626 is hereby amended to read as 10 follows: 65-1626. For the purposes of this act: 11 "Administer" means the direct application of a drug, whether by (a) 12 injection, inhalation, ingestion or any other means, to the body of a patient 13 or research subject by: (1) A practitioner or pursuant to the lawful direction of a practitioner; 14 (2) the patient or research subject at the direction and in the presence 15 16 of the practitioner; or (3) a pharmacist as authorized in K.S.A. 65-1635a, and amendments 17 18 thereto. 19 "Agent" means an authorized person who acts on behalf of or at (b) 20 the direction of a manufacturer, repackager, wholesale distributor, third-21 party logistics provider or dispenser but shall not include a common 22 carrier, public warehouseman or employee of the carrier or warehouseman 23 when acting in the usual and lawful course of the carrier's or 24 warehouseman's business. 25 "Application service provider" means an entity that sells (c) 26 electronic prescription or pharmacy prescription applications as a hosted 27 service where the entity controls access to the application and maintains the software and records on its server 28 29 (d) "Authorized distributor of record" means a wholesale distributor 30 with whom a manufacturer has established an ongoing relationship to-31 distribute the manufacturer's prescription drug. An ongoing relationship is deemed to exist between such wholesale distributor and a manufacturer-32 33 when the wholesale distributor, including any affiliated group of the wholesale distributor, as defined in section 1504 of the internal revenue 34 code, complies with any one of the following: (1) The wholesale-35 distributor has a written agreement currently in effect with the-36

1 manufacturer evidencing such ongoing relationship; and (2) the wholesale

2 distributor is listed on the manufacturer's current list of authorized

3 distributors of record, which is updated by the manufacturer on no less

than a monthly basis" Automated dispensing system" means a robotic or
mechanical system, controlled by a computer which: (1) Performs
operations or activities, other than compounding or administration,
relative to the storage, packaging, labeling, dispensing or distribution of
drugs; (2) collects, controls and maintains all transaction information;
and (3) operates in accordance with the board's rules and regulations.

10 (e) "Biological product" means a virus, a therapeutic serum, a 11 toxin, an antitoxin, a vaccine, blood, a blood polypeptide, or an 12 analogous product, arsphenamine or derivative or arphenamine, or 13 any other trivalent organic arsenic compound which is applicable to 14 the prevention, treatment or cure of a disease or condition of humans.

(e) (f) "Board" means the state board of pharmacy created by K.S.A.
 74-1603, and amendments thereto.

(f) (g) "Brand exchange" means the dispensing of a different drug
 product of the same dosage form and strength and of the same generic
 name as the brand name drug product prescribed.

20 (g) (h) "Brand name" means the registered trademark name given to a 21 drug product by its manufacturer, labeler or distributor.

(h) "Chain pharmacy warehouse" means a permanent physical location for drugs or devices, or both, that acts as a central warehouse and
 performs intracompany sales or transfers of prescription drugs or devices
 to chain pharmacies that have the same ownership or control. Chain pharmacy warehouses must be registered as wholesale distributors.

(i) (h) (i) "Co-licenseeCo-licensed partner" means-a pharmaceutical
manufacturer any person that has entered into an agreement with-another
a pharmaceutical manufacturer to engage in a business activity or
occupation related to the manufacture or distribution of a prescription drug
product and the national drug code on the drug product label shall be used
to determine the identity of the drug manufacturer.

(i) (i) (j) "Common carrier" means any person who undertakes,
 whether directly or by any other arrangement, to transport property,
 including drugs, for compensation.

36 (*i*) (**k**) "Compounding" means the combining of components into a
 37 compounded preparation under either of the following conditions:

38 (1) As the result of a practitioner's prescription drug order or 39 initiative based on the practitioner-patient-pharmacist relationship in the 40 course of professional practice, to meet the specialized medical need of an 41 individual patient of the practitioner that cannot be filled by an FDA-42 approved drug; or

43 (2) for the purpose of, or incident to, research, teaching, or chemical

1 *analysis and not for sale or dispensing.* 

2 Compounding shall include the preparation of drugs or devices in 3 anticipation of receiving prescription drug orders based on routing, 4 regularly observed prescribing patterns.

5 Compounding shall not include reconstituting any oral or topical drug 6 according to the FDA-approved labeling for the drug, or preparing any 7 sterile or nonsterile preparation that is essentially a copy of a 8 commercially available product.

9 (k) (l) "DEA" means the U.S. department of justice, drug enforcement administration.

(k) (l) (m) "Deliver" or "delivery" means the actual, constructive or attempted transfer from one person to another of any drug whether or not an agency relationship exists.

14 (1) (m) (n) "Direct supervision" means the process by which the 15 responsible pharmacist shall observe and direct the activities of a 16 pharmacy student or pharmacy technician to a sufficient degree to assure 17 that all such activities are performed accurately, safely and without risk or 18 harm to patients, and complete the final check before dispensing.

19 (m) (n) (o) "Dispense" or "dispensing" means to deliver prescription 20 medication to the ultimate user or research subject by or pursuant to the 21 lawful order of a practitioner or pursuant to the prescription of a mid-level 22 practitioner.

23

(n) (o) (p) "Dispenser" means:

24 (1) A practitioner or pharmacist who dispenses prescription 25 medication, or a physician assistant who has authority to dispense 26 prescription-only drugs in accordance with K.S.A. 65-28a08(b), and 27 amendments thereto; or

(2) a retail pharmacy, hospital pharmacy or group of pharmacies
under common ownership and control that do not act as a wholesale
distributor, or affiliated warehouses or distribution centers of such entities
under common ownership and control that do not act as a wholesale
distributor.

(o) (p) (q) "Distribute" or "distribution" means to deliver, offer to
 deliver, sell, offer to sell, purchase, trade, transfer, broker, give away,
 handle, store or receive, other than by administering or dispensing, any
 drug.

37 (p) (q) (r) "Distributor" means a person-who or entity that distributes
 38 a drug.

39 (q) (r) (s) "Drop shipment" means the sale, by a manufacturer, that 40 manufacturer's co-licensee, that manufacturer's third party logistics-41 provider, repackager or that manufacturer's exclusive distributor, of the 42 manufacturer's prescription drug, to a wholesale distributor whereby the 43 wholesale distributor takes title but not possession of such prescription

4

drug and the wholesale distributor invoices the pharmacy, the chain-1 2 pharmacy warehouse, or other designated person authorized by law todispense or administer such prescription drug, and the pharmacy, the chain 3 pharmacy warehouse, or other designated person authorized by law to-4 dispense or administer such prescription drug dispenser, and the dispenser 5 6 receives delivery of the prescription drug directly from the manufacturer, 7 that manufacturer's co-licensee, that manufacturer's repackager, third-party 8 logistics provider, or that manufacturer's exclusive distributor, of such 9 prescription drug. Drop shipment shall be part of the "normal distribution 10 channel."

11 <del>(r) (s)</del> (t) "Drug" means: (1) Articles recognized in the official United 12 States pharmacopoeia pharmacopeia, or other such official compendiums of the United States, or official national formulary, or any supplement of 13 14 any of them; (2) articles intended for use in the diagnosis, cure, mitigation, 15 treatment or prevention of disease in-man humans or other animals; (3) 16 articles, other than food, intended to affect the structure or any function of 17 the body of-man humans or other animals; and (4) articles intended for use 18 as a component of any articles specified in paragraph (1), (2) or (3) of this 19 subsection; but does not include devices or their components, parts or accessories, except that the term "drug" shall not include amygdalin 20 21 (laetrile) or any livestock remedy, if such livestock remedy had been 22 registered in accordance with the provisions of article 5 of chapter 47 of 23 the Kansas Statutes Annotated, prior to its repeal.

24 (s) (t) (u) "Durable medical equipment" means-technologically-25 sophisticated medical devices that may be used in a residence, including the following equipment that: (1) Oxygen and oxygen delivery system-26 27 Provides therapeutic benefits or enables an individual to perform certain 28 tasks that the individual is unable to otherwise undertake due to certain medical conditions or illnesses; (2) ventilators is primarily and 29 30 customarily used to serve a medical purpose; (3) respiratory disease 31 management devices generally is not useful to a person in the absence of 32 an illness or injury; (4) continuous positive airway pressure (CPAP) 33 devices can withstand repeated use; (5) electronic and computerized wheelchairs and seating systems is appropriate for use in the home, long-34 term care facility or medical care facility, but may be transported to other 35 locations to allow the individual to complete instrumental activities of 36 37 daily living, which are more complex tasks required for independent living; 38 and (6) apnea monitors; (7) transcutaneous electrical nerve stimulator-39 (TENS) units; (8) low air loss cutaneous pressure management devices; (9) sequential compression devices; (10) feeding pumps; (11) home-40 41 phototherapy devices; (12) infusion delivery devices; (13) distribution of 42 medical gases to end users for human consumption; (14) hospital beds;-43 (15) nebulizers; or (16) may include devices and medical supplies or other

similar equipment determined by the board in rules and regulations
 adopted by the board.

3 (t) (u) (v) "Electronic prescription" means an electronically prepared 4 prescription that is authorized and transmitted from the prescriber to the 5 pharmacy by means of electronic transmission.

6 (u) (v) (w) "Electronic prescription application" means software that 7 is used to create electronic prescriptions and that is intended to be installed 8 on the prescriber's computers and servers where access and records are 9 controlled by the prescriber.

10 (v) (w) (x) "Electronic signature" means a confidential personalized 11 digital key, code, number or other method for secure electronic data 12 transmissions which identifies a particular person as the source of the 13 message, authenticates the signatory of the message and indicates the 14 person's approval of the information contained in the transmission.

15 (w)(x)(y) "Electronic transmission" means the transmission of an 16 electronic prescription, formatted as an electronic data file, from a 17 prescriber's electronic prescription application to a pharmacy's computer, 18 where the data file is imported into the pharmacy prescription application.

19 (x) (y) (z) "Electronically prepared prescription" means a prescription 20 that is generated using an electronic prescription application.

21 (y) (z) (aa) "Exclusive distributor" means any entity that: (1)-22 Contracts with a manufacturer to provide or coordinate warehousing, 23 wholesale distribution or other services on behalf of a manufacturer and 24 who takes title to that manufacturer's prescription drug, but who does not 25 have general responsibility to direct the sale or disposition of themanufacturer's prescription drug; (2) is registered as a wholesale-26 27 distributor under the pharmacy act of the state of Kansas; and (3) to be-28 considered part of the normal distribution channel, must be an authorized 29 distributor of record the wholesale distributor that directly purchased the product from the manufacturer and is the sole distributor of that 30 31 manufacturer's product to a subsequent repackager, wholesale distributor 32 or dispenser.

33 (z) (aa) (bb) "FDA" means the U.S. department of health and human
 34 services, food and drug administration.

35 (bb) (cc) "Facsimile transmission" or "fax transmission" means the 36 transmission of a digital image of a prescription from the prescriber or the 37 prescriber's agent to the pharmacy. "Facsimile transmission" includes, but 38 is not limited to, transmission of a written prescription between the 39 prescriber's fax machine and the pharmacy's fax machine; transmission of 40 an electronically prepared prescription from the prescriber's electronic prescription application to the pharmacy's fax machine, computer or 41 printer; or transmission of an electronically prepared prescription from the 42 43 prescriber's fax machine to the pharmacy's fax machine, computer or

1 printer.

2 (aa) (cc) (dd) "Generic name" means the established chemical name 3 or official name of a drug or drug product.

(bb) (dd) (ee) "Health care entity" means any person that provides 4 diagnostic, medical, surgical or dental treatment or rehabilitative care but 6 does not include any retail pharmacy or wholesale distributor.

(ee) (ff) (1) "Institutional drug room" means any location where 7 8 prescription-only drugs are stored and from which prescription-only drugs 9 are administered or dispensed and which is maintained or operated for the 10 purpose of providing the drug needs of:

(A) Inmates of a jail or correctional institution or facility;

12 (B) residents of a juvenile detention facility, as defined by the revised Kansas code for care of children and the revised Kansas juvenile justice 13 14 code:

15 (C) students of a public or private university or college, a community 16 college or any other institution of higher learning which is located in 17 Kansas:

employees of a business or other employer; or

(E) persons receiving inpatient hospice services.

(2) "Institutional drug room" does not include:

18 (D)

19

20

21 22

(A) Any registered pharmacy;

(B) any office of a practitioner; or

23 (C) a location where no prescription-only drugs are dispensed and no 24 prescription-only drugs other than individual prescriptions are stored or 25 administered.

26 (ee) (ff) (gg) "Intermediary" means any technology system that 27 receives and transmits an electronic prescription between the prescriber 28 and the pharmacy.

29 <del>(dd) (gg)</del> (hh) "Intracompany transaction" means any transaction or 30 transfer between any division, subsidiary, parent or affiliated or related 31 company under common ownership or control of a corporate entity, or any 32 transaction or transfer between co-licensees of a co-licensed product co-33 licensed partners.

34 (*hh*) (ii) "Label" means a display of written, printed or graphic 35 matter upon the immediate container of any drug.

36 (ii) (jj) "Labeling" means the process of preparing and affixing a 37 label to any drug container, exclusive of the labeling by a manufacturer, 38 packer or distributor of a non-prescription drug or commercially 39 packaged legend drug.

(ii) (kk) "Long-term care facility" means "nursing facility," as 40 41 defined in K.S.A. 39-923, and amendments thereto.

42 (ee) (kk) (II) "Medical care facility" shall have the meaning provided 43 in K.S.A. 65-425, and amendments thereto, except that the term shall also

5

11

include facilities licensed under the provisions of K.S.A. 75-3307b, and 1 2 amendments thereto, except community mental health centers and facilities for people with intellectual disability. 3

(ff) (H) (mm) "Manufacture" means the production, preparation, 4 propagation, compounding, conversion or processing of a drug either 5 6 directly or indirectly by extraction from substances of natural origin, 7 independently by means of chemical or biological synthesis or by a 8 combination of extraction and chemical or biological synthesis-andincludes any or the packaging or repackaging of the drug or labeling or 9 relabeling of its container, except that this term shall not include the 10 preparation or compounding of a drug by an individual for the individual's 11 12 own use or the preparation, compounding, packaging or labeling of a drug 13 by:

(1) A practitioner or a practitioner's authorized agent incident to such 14 15 practitioner's administering or dispensing of a drug in the course of the 16 practitioner's professional practice;

17 (2) a practitioner, by a practitioner's authorized agent or under a practitioner's supervision for the purpose of, or as an incident to, research, 18 19 teaching or chemical analysis and not for sale; or

20 (3) a pharmacist or the pharmacist's authorized agent acting under the 21 direct supervision of the pharmacist for the purpose of, or incident to, the 22 dispensing of a drug by the pharmacist.

23 (gg) (mm) (nn) "Manufacturer" means a person licensed or approved 24 by the FDA to engage in the manufacture of drugs and devices:

25 (1) A person that holds an application approved under section 505 of the federal food, drug and cosmetic act or a license issued under section 26 27 351 of the federal public health service act for such drug, or if such drug 28 is not the subject of an approved application application or license, the 29 person who manufactured the drug:

30 (2) a co-licensed partner of the person described in paragraph (1) that obtains the drug directly from a person described in paragraph (1) or 31 32 (3): or

33 (3) an affiliate of a person described in paragraph (1) or (2) that receives the product directly from a person described in paragraph (1) or 34 35 (2).

36 (hh) (nn) (oo) "Mid-level practitioner" means an advanced practice 37 registered nurse issued a license pursuant to K.S.A. 65-1131, and 38 amendments thereto, who has authority to prescribe drugs pursuant to a written protocol with a responsible physician under K.S.A. 65-1130, and 39 40 amendments thereto, or a physician assistant licensed pursuant to the 41 physician assistant licensure act who has authority to prescribe drugs prior to January 11, 2016, pursuant to a written protocol with a responsible 42 43 physician under K.S.A. 65-28a08, and amendments thereto, and on and

after January 11, 2016, pursuant to a written agreement with a supervising
 physician under K.S.A. 65-28a08, and amendments thereto.
 (ii) "Normal distribution channel" means a chain of custody for a-

rescription-only drug that goes from a manufacturer of the prescription-only drug, from that manufacturer to that manufacturer's co-licensed-partner, from that manufacturer to that manufacturer's third-party logistics
 provider or from that manufacturer to that manufacturer's exclusive-distributor, directly or by drop shipment, to:

9 (1) A pharmacy to a patient or to other designated persons authorized
 10 by law to dispense or administer such drug to a patient;

11 (2) a wholesale distributor to a pharmacy to a patient or other 12 designated persons authorized by law to dispense or administer such drug
 13 to a patient;

(3) a wholesale distributor to a chain pharmacy warehouse to that
 chain pharmacy warehouse's intracompany pharmacy to a patient or other
 designated persons authorized by law to dispense or administer such drug
 to a patient; or

(4) a chain pharmacy warehouse to the chain pharmacy warehouse's
 intracompany pharmacy to a patient or other designated persons authorized
 By law to dispense or administer such drug to a patient.

21 (oo) (pp) "Nonresident pharmacy" means a pharmacy located 22 outside of Kansas.

(qq) "Outsourcing facility" or "virtual outsourcing facility"
 means a facility at one geographic location or address that is engaged in
 the compounding of sterile drugs and has registered with the FDA as an
 outsourcing facility pursuant to 21 U.S.C. § 353b.

(jj) (qq) (rr) "Person" means individual, corporation, government,
 governmental subdivision or agency, partnership, association or any other
 legal entity.

30 (kk) (rr) (ss) "Pharmacist" means any natural person licensed under
 31 this act to practice pharmacy.

(II) (ss) (tt) "Pharmacist-in-charge" means the pharmacist who is 32 33 responsible to the board for a registered establishment's compliance with the laws and regulations of this state pertaining to the practice of 34 pharmacy, manufacturing of drugs and the distribution of drugs. The 35 pharmacist-in-charge shall supervise such establishment on a full-time or a 36 37 part-time basis and perform such other duties relating to supervision of a 38 registered establishment as may be prescribed by the board by rules and 39 regulations. Nothing in this definition shall relieve other pharmacists or 40 persons from their responsibility to comply with state and federal laws and regulations. 41

42 (mm) (tt) (uu) "Pharmacist intern" means: (1) A student currently 43 enrolled in an accredited pharmacy program; (2) a graduate of an accredited pharmacy program serving an internship; or (3) a graduate of a
 pharmacy program located outside of the United States which is not
 accredited and who has successfully passed equivalency examinations
 approved by the board.

5 (nn) (uu) (vv) "Pharmacy," "drugstore" or "apothecary" means 6 premises, laboratory, area or other place: (1) Where drugs are offered for 7 sale where the profession of pharmacy is practiced and where prescriptions 8 are compounded and dispensed;-or (2) which has displayed upon it or within it the words "pharmacist," "pharmaceutical chemist," "pharmacy," 9 "apothecary," "drugstore," "druggist," "drugs," "drug sundries" or any of 10 these words or combinations of these words or words of similar import 11 12 either in English or any sign containing any of these words; or (3) where the characteristic symbols of pharmacy or the characteristic prescription 13 sign "Rx" may be exhibited. As used in this subsection, premises refers 14 15 only to the portion of any building or structure leased, used or controlled 16 by the licensee in the conduct of the business registered by the board at the 17 address for which the registration was issued.

(oo) (vv) (ww) "Pharmacy prescription application" means software
 that is used to process prescription information, is installed on a
 pharmacy's computers or servers, and is controlled by the pharmacy.

(pp) (ww) (xx) "Pharmacy technician" means an individual who, under the direct supervision and control of a pharmacist, may perform packaging, manipulative, repetitive or other nondiscretionary tasks related to the processing of a prescription or medication order and who assists the pharmacist in the performance of pharmacy related duties, but who does not perform duties restricted to a pharmacist.

27 (qq) (xx) (yy) "Practitioner" means a person licensed to practice 28 medicine and surgery, dentist, podiatrist, veterinarian, optometrist or 29 scientific investigator or other person authorized by law to use a 30 prescription-only drug in teaching or chemical analysis or to conduct 31 research with respect to a prescription-only drug.

(rr) (yy) (zz) "Preceptor" means a licensed pharmacist who possesses
 at least two years' experience as a pharmacist and who supervises students
 obtaining the pharmaceutical experience required by law as a condition to
 taking the examination for licensure as a pharmacist.

36 (ss) (zz) (aaa) "Prescriber" means a practitioner or a mid-level
 37 practitioner.

38 (tt) (aaa) (bbb) "Prescription" or "prescription order" means: (1) An 39 order to be filled by a pharmacist for prescription medication issued and 40 signed by a prescriber in the authorized course of such prescriber's 41 professional practice; or (2) an order transmitted to a pharmacist through 42 word of mouth, note, telephone or other means of communication directed 43 by such prescriber, regardless of whether the communication is oral, 1 electronic, facsimile or in printed form.

(uu) (bbb) (ccc) "Prescription medication" means any drug, including
 label and container according to context, which is dispensed pursuant to a
 prescription order.

5 (vv) (ccc) (ddd) "Prescription-only drug" means any drug whether 6 intended for use by-man human or animal, required by federal or state law, 7 including 21 U.S.C. § 353, to be dispensed only pursuant to a written or 8 oral prescription or order of a practitioner or is restricted to use by 9 practitioners only.

10 (ww) (ddd) (eee) "Probation" means the practice or operation under a 11 temporary license, registration or permit or a conditional license, 12 registration or permit of a business or profession for which a license, 13 registration or permit is granted by the board under the provisions of the 14 pharmacy act of the state of Kansas requiring certain actions to be 15 accomplished or certain actions not to occur before a regular license, 16 registration or permit is issued.

(xx) (eee) (fff) "Product" means a prescription drug in a finisheddosage form for administration to a patient without substantial furthermanufacturing, including, but not limited to, capsules, tablets andlyophilized products before reconstitution shall have the meaning as
defined by part H of the federal drug supply chain security act, 21
U.S.C. § 351 et seq., 21 U.S.C. § 360eee.

23

(fff) (ggg) "Professional incompetency" means:

(1) One or more instances involving failure to adhere to the
 applicable standard of pharmaceutical care to a degree which constitutes
 gross negligence, as determined by the board;

(2) repeated instances involving failure to adhere to the applicable
 standard of pharmaceutical care to a degree which constitutes ordinary
 negligence, as determined by the board; or

30 (3) a pattern of pharmacy practice or other behavior which 31 demonstrates a manifest incapacity or incompetence to practice pharmacy.

32 (yy) (ggg) (hhh) "Readily retrievable" means that records kept by 33 automatic data processing applications or other electronic or mechanized 34 record-keeping systems can be separated out from all other records within 35 a reasonable time not to exceed 48 hours of a request from the board or 36 other authorized agent or that hard-copy records are kept on which certain 37 items are asterisked, redlined or in some other manner visually identifiable 38 apart from other items appearing on the records.

39 (*hhh*) (iii) "Repackage" means changing the container, wrapper,
 40 quantity or label of a drug to further the distribution of the drug.

41 (iii) (jjj) "Repackager" means a person who owns or operates a 42 facility that repackages.

43 (zz) (jjj) (III) "Retail dealer" means a person selling at retail

nonprescription drugs which are prepackaged, fully prepared by the 1 manufacturer or distributor for use by the consumer and labeled in 2 accordance with the requirements of the state and federal food, drug and 3 cosmetic acts. Such nonprescription drugs shall not include: (1) A 4 5 controlled substance; (2) a prescription-only drug; or (3) a drug intended 6 for human use by hypodermic injection.

7 (*III*) (**mmm**) "Return" means providing product to the authorized 8 immediate trading partner from which such product was purchased or 9 received, or to a returns processor or reverse logistics provider for 10 handling of such product.

(mmm) (nnn) "Returns processor" or "reverse logistics provider" 11 12 means a person who owns or operates an establishment that disposes of or otherwise processes saleable or nonsaleable products received from an 13 authorized trading partner such that the product may be processed for 14 15 credit to the purchaser, manufacturer or seller, or disposed of for no 16 *further distribution.* 

17 (aaa) (nnn) (000) "Secretary" means the executive secretary of the 18 board.

19 (bbb) (ooo) (ppp) "Third-party logistics provider" means an entity 20 that: (1) provides or coordinates warehousing, distribution or other *logistic* 21 services of a product in interstate commerce on behalf of a manufacturer, 22 wholesale distributor or dispenser, but does not take title to the 23 prescription drug ownership of the product or have general responsibility to direct the prescription drug's sale or disposition of the product; (2) is 24 25 registered as a wholesale distributor under the pharmaev act of the state of 26 Kansas: and (3) to be considered part of the normal distribution channel. 27 must also be an authorized distributor of record.

28

(ppp) (qqq) "Trading partner" means:

29 (1) A manufacturer, repackager, wholesale distributor or dispenser from whom a manufacturer, repackager, wholesale distributor or dispenser 30 accepts direct ownership of a product or to whom a manufacturer, 31 repackager, wholesale distributor or dispenser transfers direct 32 33 ownership of a product; or

34 (2) a third-party logistics provider from whom a manufacturer, 35 repackager, wholesale distributor or dispenser accepts direct possession 36 of a product or to whom a manufacturer, repackager, wholesale distributor 37 or dispenser transfers direct possession of a product.

38 (qqq) (rrr) "Transaction" means the transfer of product between 39 persons in which a change of ownership occurs.

(ecc) (rrr) (sss) "Unprofessional conduct" means: 40 41

(1) Fraud in securing a registration or permit;

(2) intentional adulteration or mislabeling of any drug, medicine, 42 43 chemical or poison;

1 (3) causing any drug, medicine, chemical or poison to be adulterated 2 or mislabeled, knowing the same to be adulterated or mislabeled;

(4) intentionally falsifying or altering records or prescriptions;

4 (5) unlawful possession of drugs and unlawful diversion of drugs to 5 others;

6 (6) willful betrayal of confidential information under K.S.A. 65-1654, 7 and amendments thereto;

8

(7) conduct likely to deceive, defraud or harm the public;

9 (8) making a false or misleading statement regarding the licensee's 10 professional practice or the efficacy or value of a drug;

11 (9) commission of any act of sexual abuse, misconduct or 12 exploitation related to the licensee's professional practice; or

(10) performing unnecessary tests, examinations or services whichhave no legitimate pharmaceutical purpose.

(ddd) (sss) (ttt) "Vaccination protocol" means a written protocol, agreed to by a pharmacist and a person licensed to practice medicine and surgery by the state board of healing arts, which establishes procedures and recordkeeping and reporting requirements for administering a vaccine by the pharmacist for a period of time specified therein, not to exceed two years.

21 (eee) (*ttt*) (uuu) "Valid prescription order" means a prescription that 22 is issued for a legitimate medical purpose by an individual prescriber 23 licensed by law to administer and prescribe drugs and acting in the usual 24 course of such prescriber's professional practice. A prescription issued 25 solely on the basis of an internet-based questionnaire or consultation 26 without an appropriate prescriber-patient relationship is not a valid 27 prescription order.

28 (fff) (uuu) (vvv) "Veterinary medical teaching hospital pharmacy" 29 means any location where prescription-only drugs are stored as part of an 30 accredited college of veterinary medicine and from which prescription-31 only drugs are distributed for use in treatment of or administration to a 32 nonhuman.

(ggg) (vvv) (www) "Wholesale distributor" means any person
 engaged in wholesale distribution of prescription drugs or devices in or
 into the state, including, but not limited to, manufacturers, repackagers,
 own-label distributors, private-label distributors, jobbers, brokers,
 warehouses, including manufacturers' and distributors' warehouses, co-

38 licensees, exclusive distributors, third party logistics providers, chain-

39 pharmacy warehouses that conduct wholesale distributions, and wholesale

40 drug warehouses, independent wholesale drug traders and retail-41 pharmacies that conduct wholesale distributions. Wholesale distributor-

41 pharmacies that conduct wholesale distributions. Wholesale distributor 42 shall not include persons engaged in the sale of durable medical equipment

43 to consumers or patients, other than a manufacturer, co-licensed partner,

3 4

1 *third-party logistics provider, or repackager.* 

(hhh) (www) (xxx) "Wholesale distribution" means the distribution or 2 3 receipt of prescription drugs or devices by wholesale distributors to or by persons other than consumers or patients, and includes the transfer of 4 prescription drugs by a pharmacy to another pharmacy if the total number 5 6 of units of transferred drugs during a twelve-month period does not exceed 7 5% of the total number of all units dispensed by the pharmacy during the 8 immediately preceding twelve-month period. Wholesale distribution does 9 not include:

(1) The-sale, purchase or trade of a prescription drug or device, an
 offer to sell, purchase or trade a prescription drug or device or the dispensing of a prescription drug-or device pursuant to a prescription;

13 (2) the sale, purchase or trade distribution of a prescription drug-or 14 device or an offer to-sell, purchase or trade distribute a prescription drug-or 15 device for emergency medical reasons, including a public health 16 emergency declaration pursuant to section 319 of the public health service 17 act, except that, for purposes of this paragraph, a drug shortage not 18 caused by a public health emergency shall not constitute an emergency 19 medical reason;

(3) intracompany transactions, as defined in this section, unless in violation of own use provisions distribution of any drug between members
 of an affiliate or within a manufacturer;

(4) the sale, purchase or trade distribution of a prescription drug-or
 device or an offer to-sell, purchase or trade distribute a prescription drug-or
 device among hospitals, chain pharmacy warehouses, pharmacies or other
 health care entities that are under common control;

(5) the sale, purchase or trade distribution of a prescription drug-or
device or the offer to-sell, purchase or trade distribute a prescription drug
or device by a charitable organization described in 503(c)(3) of the internal
revenue code of 1954 to a nonprofit affiliate of the organization to the
extent otherwise permitted by law;

32 (6) the purchase or other acquisition by a *dispenser*, hospital or other 33 similar health care entity—that is a member of a group purchasing-34 organization of a prescription drug or device for its own use from the-35 group purchasing organization or from other hospitals or similar health 36 eare entities that are members of these organizations for use by such 37 dispenser, hospital or other health care entity;

(7) the transfer of prescription drugs or devices between pharmacies
 pursuant to a centralized prescription processing agreement the
 distribution of a drug by the manufacturer of such drug;

41 (8) the sale, purchase or trade of blood and blood components42 intended for transfusion the receipt or transfer of a drug by an authorized
43 third-party logistics provider, provided that such third-party logistics

1 provider does not take ownership of the drug;

2 (9) the return of recalled, expired, damaged or otherwise non-salable 3 prescription drugs, when conducted by a hospital, health care entity, 4 pharmacy, chain pharmacy warehouse or charitable institution in-5 accordance with the board's rules and regulations a common carrier that 6 transports a drug, provided that the common carrier does not take 7 ownership of the drug;

8 (10) the sale, transfer, merger or consolidation of all or part of the 9 business of a retail pharmacy or pharmacies from or with another retailpharmacy or pharmacies, whether accomplished as a purchase and sale of 10 stock or business assets, in accordance with the board's rules and 11 regulations the distribution of a drug, or an offer to distribute a drug by an 12 authorized repackager that has taken ownership or possession of the drug 13 14 and repacks it in accordance with section 582(e) of the federal food, drug 15 and cosmetic act:

16 (11) the distribution of drug samples by manufacturers' and 17 authorized distributors' representatives saleable drug returns when 18 conducted by a dispenser;

(12) the sale distribution of minimal quantities of drugs by licensed
 retail pharmacies to licensed practitioners for office use;

(13) the distribution of a collection of finished medical devices,
which may include a product or biological product in accordance with 21
U.S.C. § 353(e)(4)(M);

(14) the distribution of an intravenous drug that, by its formulation,
is intended for the replenishment of fluids and electrolytes, including
sodium, chloride and potassium, or calories, including dextrose and
amino acids;

28 (15) the distribution of an intravenous drug used to maintain the 29 equilibrium of water and minerals in the body, such as dialysis solutions;

30 (16) the distribution of a drug that is intended for irrigation, or 31 sterile water, whether intended for such purposes or for injection;

32

(17) the distribution of medical gas;

(18) facilitating the distribution of a product by providing solely
 administrative services, including processing of orders and payments;

(19) the transfer of a product by a hospital or other health care 35 entity, or by a wholesale distributor or manufacturer operating under the 36 37 direction of a hospital or other health care entity, to a repackager 38 described in section 581(16)(B) and registered under section 510 of the 39 food, drug and cosmetic act for the purpose of repackaging the drug for use by that hospital or other health care entity, or other health care 40 entities under common control, if ownership of the drug remains with the 41 hospital or other health care entity at all times; or 42

43 (13) (20) the sale or transfer from a retail pharmacy-or chain-

pharmacy warchouse of expired, damaged, returned or recalled
 prescription drugs to the original manufacturer, originating wholesale
 distributor or to a third-party returns processor in accordance with the
 board's rules and regulations.

5 Sec. 2. K.S.A. 2015 Supp. 65-1627 is hereby amended to read as 6 follows: 65-1627. (a) The board may revoke, suspend, place in a 7 probationary status or deny-a *an application or* renewal of any license of 8 any pharmacist upon a finding that:

9 (1) The-license was obtained by licensee has obtained, renewed or 10 reinstated, or attempted to obtain, renew or reinstate, a license by false or 11 fraudulent means, including misrepresentation of a material fact;

12 (2) the licensee has been convicted of a *misdemeanor involving* 13 *moral turpitude or gross immorality or any* felony and the licensee fails to 14 show that the licensee has been sufficiently rehabilitated to warrant the 15 public trust;

(3) the licensee is found by the board to be guilty of unprofessionalconduct or professional incompetency;

(4) the licensee is addicted to the liquor or drug habit to such a degreeas to render the licensee unfit to practice the profession of pharmacy;

(5) the licensee has violated a provision of the federal or state food,
drug and cosmetic act, the uniform controlled substances act of the state of
Kansas, or any rule and regulation adopted under any such act;

(6) the licensee is found by the board to have filled a prescription not
 in strict accordance with the directions of the practitioner or a mid-level
 practitioner;

26 (7) the licensee is found to be mentally or physically incapacitated to
27 such a degree as to render the licensee unfit to practice the profession of
28 pharmacy;

(8) the licensee has violated any of the provisions of the pharmacy act
of the state of Kansas or any rule and regulation adopted by the board
pursuant to the provisions of such pharmacy act;

(9) the licensee has failed to comply with the *continuing education* requirements of the board-relating to the continuing education of pharmacists for license renewal;

(11) the licensee has knowingly submitted a misleading, deceptive,untrue or fraudulent misrepresentation on a claim form, bill or statement;

41 (12) the licensee has had a license to practice pharmacy revoked,
42 suspended or limited, has been censured or has had other disciplinary
43 action taken, or voluntarily surrendered the license after formal

1 proceedings have been commenced, or has had an application for license

2 denied, by the proper licensing authority of another state, territory, District
3 of Columbia or other country, a certified copy of the record of the action of
4 the other jurisdiction being conclusive evidence thereof;

5 (13) the licensee has self-administered any controlled substance 6 without a practitioner's prescription order or a mid-level practitioner's 7 prescription order; or

8 (14) the licensee has assisted suicide in violation of K.S.A. 21-3406, 9 prior to its repeal, or K.S.A. 2015 Supp. 21-5407, and amendments 10 thereto, as established by any of the following:

(A) A copy of the record of criminal conviction or plea of guilty for a
felony in violation of K.S.A. 21-3406, prior to its repeal, or K.S.A. 2015
Supp. 21-5407, and amendments thereto.

14 (B) A copy of the record of a judgment of contempt of court for 15 violating an injunction issued under K.S.A. 60-4404, and amendments 16 thereto.

17 (C) A copy of the record of a judgment assessing damages under
 18 K.S.A. 60-4405, and amendments thereto; or

(15) the licensee has failed to furnish the board, its investigators or its
 representatives any information legally requested by the board; or

(16) the licensee has violated or failed to comply with any lawful
order or directive of the board.

23 (b) In determining whether or not the licensee has violated subsection 24 (a)(3), (a)(4), (a)(7) or (a)(13), the board upon reasonable suspicion of 25 such violation has authority to compel a licensee to submit to mental or physical examination or drug screen, or any combination thereof, by such 26 27 persons as the board may designate. To determine whether reasonable 28 suspicion of such violation exists, the investigative information shall be 29 presented to the board as a whole. Information submitted to the board as a 30 whole and all reports, findings and other records shall be confidential and 31 not subject to discovery by or release to any person or entity. The licensee 32 shall submit to the board a release of information authorizing the board to 33 obtain a report of such examination or drug screen, or both. A person 34 affected by this subsection shall be offered, at reasonable intervals, an 35 opportunity to demonstrate that such person can resume the competent 36 practice of pharmacy with reasonable skill and safety to patients. For the 37 purpose of this subsection, every person licensed to practice pharmacy and 38 who shall accept the privilege to practice pharmacy in this state by so 39 practicing or by the making and filing of a renewal application to practice 40 pharmacy in this state shall be deemed to have consented to submit to a 41 mental or physical examination or a drug screen, or any combination 42 thereof, when directed in writing by the board and further to have waived 43 all objections to the admissibility of the testimony, drug screen or

1 examination report of the person conducting such examination or drug 2 screen, or both, at any proceeding or hearing before the board on the 3 ground that such testimony or examination or drug screen report 4 constitutes a privileged communication. In any proceeding by the board pursuant to the provisions of this subsection, the record of such board 5 6 proceedings involving the mental and physical examination or drug screen, 7 or any combination thereof, shall not be used in any other administrative 8 or judicial proceeding.

9 (c) The board may temporarily suspend or temporarily limit the 10 license of any licensee in accordance with the emergency adjudicative 11 proceedings under the Kansas administrative procedure act if the board 12 determines that there is cause to believe that grounds exist for disciplinary 13 action under subsection (a) against the licensee and that the licensee's 14 continuation in practice would constitute an imminent danger to the public 15 health and safety.

16 (d) The board may suspend, revoke, place in a probationary status or 17 deny a renewal of any retail dealer's permit issued by the board when 18 information in possession of the board discloses that such operations for 19 which the permit was issued are not being conducted according to law or the rules and regulations of the board. When the board determines that 20 21 action under this subsection requires the immediate protection of the 22 public interest, the board shall conduct an emergency proceeding in 23 accordance with K.S.A. 77-536, and amendments thereto, under the 24 Kansas administrative procedure act.

(e) The board may revoke, suspend, place in a probationary status ordeny a renewal of the registration of a pharmacy upon a finding that:

(1) Such pharmacy has been operated in such manner that violations
of the provisions of the pharmacy act of the state of Kansas or of the rules
and regulations of the board have occurred in connection therewith;

(2) the owner or any pharmacist employed at such pharmacy is
convicted, subsequent to such owner's acquisition of or such employee's
employment at such pharmacy, of a violation of the pharmacy act or
uniform controlled substances act of the state of Kansas, or the federal or
state food, drug and cosmetic act;

(3) the owner or any pharmacist employed by such pharmacy hasfraudulently claimed money for pharmaceutical services; or

(4) the registrant has had a registration revoked, suspended or limited, has been censured or has had other disciplinary action taken, or an application for registration denied, by the proper registering authority of another state, territory, District of Columbia or other country, a certified copy of the record of the action of the other jurisdiction being conclusive evidence thereof.

43 When the board determines that action under this subsection requires

the immediate protection of the public interest, the board shall conduct an
 emergency proceeding in accordance with K.S.A. 77-536, and
 amendments thereto, under the Kansas administrative procedure act.

4 (f) A registration to manufacture *or repackage* drugs, to distribute at 5 *operate as a* wholesale a drug *distributor*, to sell durable medical 6 equipment *or to operate as a third-party logistics provider*, or a 7 registration for the place of business where any such operation is 8 conducted, may be suspended, revoked, placed in a probationary status or 9 the renewal of such registration may be denied by the board upon a finding 10 that the registrant or the registrant's agent:

11 (1) Has materially falsified any application filed pursuant to or 12 required by the pharmacy act of the state of Kansas;

(2) has been convicted of a felony under any federal or state lawrelating to the manufacture or distribution of drugs;

(3) has had any federal registration for the manufacture or distributionof drugs suspended or revoked;

(4) has refused to permit the board or its duly authorized agents to
inspect the registrant's establishment in accordance with the provisions of
K.S.A. 65-1629, and amendments thereto;

(5) has failed to keep, or has failed to file with the board or has
falsified records required to be kept or filed by the provisions of the
pharmacy act of the state of Kansas or by the board's rules and regulations;
or

24 (6) has violated the pharmacy act of the state of Kansas or rules and 25 regulations adopted by the state board of pharmacy under the pharmacy act of the state of Kansas-or. has violated the uniform controlled substances 26 27 act or rules and regulations adopted by the state board of pharmacy under 28 the uniform controlled substances act or has violated a provision of the 29 federal drug supply chain security act or any rule or regulation adopted 30 under such act. When the board determines that action under this 31 subsection requires the immediate protection of the public interest, the 32 board shall conduct an emergency proceeding in accordance with K.S.A. 33 77-536, and amendments thereto, under the Kansas administrative 34 procedure act.

35 (g) Orders under this section, and proceedings thereon, shall be 36 subject to the provisions of the Kansas administrative procedure act.

Sec. 3. K.S.A. 65-1633 is hereby amended to read as follows: 65-1633. Every pharmacist who changes residential address *or email address* shall within 30 days thereof by letter notify the executive secretary of the board of such change *on a form prescribed and furnished by the board*, and upon receipt of the notice the executive secretary shall make the proper alterations in the record kept for that purpose.

43 Sec. 4. K.S.A. 65-1635 is hereby amended to read as follows: 65-

1 1635. (a) Nothing contained in the pharmacy act of the state of Kansas 2 shall prohibit any duly licensed practitioner from purchasing and keeping 3 drugs, from compounding prescriptions or from administering, supplying 4 or dispensing to such practitioner's patients such drugs as may be fit, 5 proper and necessary. Except as provided in subsection (b) or (c), such 6 drugs shall be dispensed by such practitioner and shall comply with the 7 Kansas food, drug and cosmetic act and be subject to inspection as 8 provided by law.

9 (b) Nothing contained in the pharmacy act of the state of Kansas shall 10 be construed to prohibit any nurse or other person, acting under the 11 direction of a duly licensed practitioner, from administering drugs to a 12 patient.

13 (c) Nothing contained in the pharmacy act of the state of Kansas shall be construed to prohibit any registered nurse, acting under the supervision 14 of a person who is licensed to practice medicine and surgery as of July 1, 15 16 1982, from dispensing drugs to patients of such person so long as the 17 principal office of such person is, and as of July 1, 1982, was, located in a 18 city not having a registered pharmacy within its boundaries. For the 19 purposes of this subsection (c), "supervision" means guidance and 20 direction of the dispensing of drugs by the person licensed to practice 21 medicine and surgery who shall be physically present in the general 22 location at which the drugs are being dispensed.

(d) Nothing contained in the pharmacy act of the state of Kansas shall
be construed to prohibit a duly registered-wholesaler wholesale distributor
from distributing a prescription-only drug pursuant to a veterinarian
practitioner's written prescription or order, where a valid veterinarianclient-patient relationship, VCPR, as defined in K.S.A. 47-816, and
amendments thereto, exists, to the layman responsible for the control of
the animal.

Sec. 5. K.S.A. 2015 Supp. 65-1636 is hereby amended to read as follows: 65-1636. (a) Except as otherwise provided in this act, the sale and distribution *dispensing* of drugs shall be limited to pharmacies operating under registrations as required by this act, and the actual sale or distribution *dispensing* of drugs shall be made by a pharmacist or other persons acting under the immediate personal direction and supervision of the pharmacist.

(b) The donation, acceptance, transfer, distribution or dispensing of
any drug in compliance with the provisions of the utilization of unused
medications act and any rules and regulations promulgated thereunder
shall not constitute a violation of this section.

41 Sec. 6. K.S.A. 2015 Supp. 65-1637 is hereby amended to read as
42 follows: 65-1637. In every store, shop or other place defined in this act as
43 a "pharmacy" there shall be a pharmacist in charge and, except as-

HB 2614—Am. by HC

20

otherwise provided by law, the compounding and dispensing of-1 2 prescriptions shall be limited to pharmacists only. Except as otherwise-3 provided by the pharmacy act of this state, when a pharmacist is not in 4 attendance at a pharmacy, the premises shall be enclosed and secured.-5 Prescription orders may be written, oral, telephonic or by electronic-6 transmission unless prohibited by law. Blank forms for written prescription 7 orders may have two signature lines. If there are two lines, one signature 8 line shall state: "Dispense as written" and the other signature line shall-9 state: "Brand exchange permissible." Prescriptions shall only be filled or 10 refilled in accordance with the following requirements: 11 (a) All prescriptions shall be filled in strict conformity with any 12 directions of the prescriber, except: 13 (1) That a pharmacist may provide up to three-month supply of aprescription drug that is not a controlled substance or psychotherapeutie-14 15 drug when a practitioner has written a drug order to be filled with a 16 smaller supply but included sufficient numbers of refills for a three-month 17 supply; and 18 (2) that a pharmacist who receives a prescription order for a brand-19 name drug product may exercise brand exchange with a view toward 20 achieving a lesser cost to the purchaser unless: 21 (A) The prescriber, in the case of a prescription signed by the-22 prescriber and written on a blank form containing two signature lines. 23 signs the signature line following the statement "dispense as written," 24 (B) the prescriber, in the case of a prescription signed by theprescriber, writes in the prescriber's own handwriting "dispense as written" 25 26 on the prescription, 27 (C) the prescriber, in the case of a prescription other than one in-28 writing signed by the prescriber, expressly indicates the prescription is to 29 be dispensed as communicated, or 30 (D) the federal food and drug administration has determined that a 31 drug product of the same generic name is not bioequivalent to the 32 prescribed brand name prescription medication. 33 (b) Prescription orders shall be recorded in writing by the pharmacist 34 and the record so made by the pharmaeist shall constitute the original-35 prescription to be dispensed by the pharmacist. This record, if telephoned 36 by other than the physician shall bear the name of the person so-37 telephoning. Nothing in this paragraph shall be construed as altering or-38 affecting in any way laws of this state or any federal act requiring a written 39 prescription order. 40 (c) (1) Except as provided in paragraph (2), no prescription shall be refilled unless authorized by the preseriber either in the original 41 42 prescription or by oral order which is reduced promptly to writing and-

43 filled by the pharmaeist.

(2) A pharmacist may refill a prescription order issued on or after the 1 2 effective date of this act for any prescription drug except a drug listed on schedule II of the uniform controlled substances act or a narcotic drug-3 listed on any schedule of the uniform controlled substances act without the 4 5 prescriber's authorization when all reasonable efforts to contact the 6 prescriber have failed and when, in the pharmacist's professional-7 judgment, continuation of the medication is necessary for the patient's-8 health, safety and welfare. Such prescription refill shall only be in an-9 amount judged by the pharmacist to be sufficient to maintain the patient until the prescriber can be contacted, but in no event shall a refill under-10 this paragraph be more than a seven day supply or one package of the 11 drug. However, if the prescriber states on a prescription that there shall be 12 no emergency refilling of that prescription, then the pharmacist shall not 13 dispense any emergency medication pursuant to that prescription. A 14 15 pharmacist who refills a prescription order under this subsection (c)(2) 16 shall contact the prescriber of the prescription order on the next business day subsequent to the refill or as soon thereafter as possible. No-17 18 pharmacist shall be required to refill any prescription order under this-19 subsection (c)(2). A prescriber shall not be subject to liability for anydamages resulting from the refilling of a prescription order by a-20 21 pharmacist under this subsection (c)(2) unless such damages are-22 occasioned by the gross negligence or willful or wanton acts or omissions 23 by the prescriber.

(d) If any prescription order contains a provision that the prescription
 may be refilled a specific number of times within or during any particular
 period, such prescription shall not be refilled except in strict conformity
 with such requirements.

(c) If a prescription order contains a statement that during any particular time the prescription may be refilled at will, there shall be no
 limitation as to the number of times that such prescription may be refilled
 except that it may not be refilled after the expiration of the time specified
 or one year after the prescription was originally issued, whichever occurs
 first.

(f) Any pharmacist who exercises brand exchange and dispenses a
 less expensive drug product shall not charge the purchaser more than the
 regular and customary retail price for the dispensed drug.

Nothing contained in this section shall be construed as preventing a pharmacist from refusing to fill or refill any prescription if in the pharmacist's professional judgment and discretion such pharmacist is of the opinion that it should not be filled or refilled. (a) The pharmacist shall exercise professional judgment regarding the accuracy, validity and authenticity of any prescription order consistent with federal and state laws and rules and regulations. A pharmacist shall not dispense a 1 prescription drug if the pharmacist, in the exercise of professional 2 judgment, determines that the prescription is not a valid prescription 3 order.

4 (b) The prescriber may authorize an agent to transmit to the 5 pharmacy a prescription order orally, by facsimile transmission or by 6 electronic transmission, provided that the first and last names of the 7 transmitting agent are included in the order.

8 (c) (1) A new written or electronically prepared and transmitted 9 prescription order shall be manually or electronically signed by the 10 prescriber. If transmitted by the prescriber's agent, the first and last names 11 of the transmitting agent shall be included in the order.

(2) If the prescription is for a controlled substance and is written or
printed from an electronic prescription application, the prescription shall
be manually signed by the prescriber prior to delivery of the prescription
to the patient or prior to facsimile transmission of the prescription to the
pharmacy.

(3) An electronically prepared prescription shall not be electronically
transmitted to the pharmacy if the prescription has been printed prior to
electronic transmission. An electronically prepared and transmitted
prescription which is printed following electronic transmission shall be
clearly labeled as a copy, not valid for dispensing.

(4) The board is hereby authorized to conduct pilot projects related to any new technology implementation when deemed necessary and practicable, except that no state moneys shall be expended for such purpose.

(d) An authorization to refill a prescription order or to renew or
continue an existing drug therapy may be transmitted to a pharmacist
through oral communication, in writing, by facsimile transmission or by
electronic transmission initiated by or directed by the prescriber.

(1) If the transmission is completed by the prescriber's agent, and the
first and last names of the transmitting agent are included in the order, the
prescriber's signature is not required on the fax or alternate electronic
transmission.

(2) If the refill order or renewal order differs in any manner from the
original order, such as a change of the drug strength, dosage form or
directions for use, the prescriber shall sign the order as provided by
subsection (c)(1).

(e) Regardless of the means of transmission to a pharmacy, only a
pharmacist or a pharmacist intern shall be authorized to receive a new
prescription order from a prescriber or transmitting agent. A pharmacist,
a pharmacist intern or a registered pharmacy technician may receive a
refill or renewal order from a prescriber or transmitting agent if such
registered pharmacy technician's supervising pharmacist has authorized

HB 2614—Am. by HC

1 *that function*.

2 (f) A refill is one or more dispensings of a prescription drug or device
3 that results in the patient's receipt of the quantity authorized by the
4 prescriber for a single fill as indicated on the prescription order.

5 *A prescription for a schedule III, IV or V controlled substance may* 6 *authorize no more than five refills within six months following the date on* 7 *which the prescription is issued.* 

8 (g) All prescriptions shall be filled or refilled in strict conformity with 9 any directions of the prescriber, except:

10 (1) That a pharmacist who receives a prescription order for a brand 11 name drug product, excluding a biological product, may exercise brand 12 exchange with a view toward achieving a lesser cost to the purchaser 13 unless:

(A) The prescriber, in the case of a prescription electronically signed
by the prescriber, includes the statement "dispense as written" on the
prescription;

(B) the prescriber, in the case of a written prescription signed by the
prescriber, writes in the prescriber's own handwriting "dispense as
written" on the prescription;

20 (C) the prescriber, in the case of a prescription other than one in 21 writing signed by the prescriber, expressly indicates the prescription is to 22 be dispensed as communicated; or

(D) the federal food and drug administration has determined that a
 drug product of the same generic name is not bioequivalent to the
 prescribed brand name prescription medication; and

(2) that a pharmacist may provide up to a three-month supply of a
prescription drug that is not a controlled substance or psychotherapeutic
drug when a practitioner has written a drug order to be filled with a
smaller supply but included sufficient numbers of refills for a three-month
supply.

(h) If a prescription order contains a statement that during any
particular time the prescription may be refilled at will, there shall be no
limitation as to the number of times that such prescription may be refilled,
except that it may not be refilled after the expiration of the time specified
or one year after the prescription was originally issued, whichever occurs
first.

(i) Prescription orders shall be recorded in writing by the pharmacist
and the record so made by the pharmacist shall constitute the original
prescription to be dispensed by the pharmacist. This record, if telephoned
by other than the prescriber, shall bear the full name of the person so
telephoning. Nothing in this section shall be construed as altering or
affecting in any way laws of this state or any federal act requiring a
written prescription order.

1 (*j*) (1) Except as provided in paragraph (2), no prescription shall be 2 refilled unless authorized by the prescriber either in the original 3 prescription or by oral order which is reduced promptly to writing and 4 filled by the pharmacist.

5 (2) A pharmacist may refill a prescription order issued on or after the 6 effective date of this act for any prescription drug, except a drug listed on 7 schedule II of the uniform controlled substances act or a narcotic drug listed on any schedule of the uniform controlled substances act. without 8 the prescriber's authorization when all reasonable efforts to contact the 9 prescriber have failed and when, in the pharmacist's professional 10 judgment, continuation of the medication is necessary for the patient's 11 12 health, safety and welfare. Such prescription refill shall only be in an amount judged by the pharmacist to be sufficient to maintain the patient 13 14 until the prescriber can be contacted, but in no event shall a refill under 15 this paragraph be more than a seven-day supply or one package of the 16 drug. However, if the prescriber states on a prescription that there shall be 17 no emergency refilling of that prescription, then the pharmacist shall not 18 dispense any emergency medication pursuant to that prescription. A 19 pharmacist who refills a prescription order under this subsection (j)(2)shall contact the prescriber of the prescription order on the next business 20 21 day subsequent to the refill or as soon thereafter as possible. No pharmacist shall be required to refill any prescription order under this 22 23 subsection (j)(2). A prescriber shall not be subject to liability for any 24 damages resulting from the refilling of a prescription order by a 25 pharmacist under this subsection (i)(2) unless such damages are 26 occasioned by the gross negligence or willful or wanton acts or omissions 27 *by the prescriber.* 

(k) If any prescription order contains a provision that the
prescription may be refilled a specific number of times within or during
any particular period, such prescription shall not be refilled except in
strict conformity with such requirements.

(1) Any pharmacist who exercises brand exchange and dispenses a
 less expensive drug product shall not charge the purchaser more than the
 regular and customary retail price for the dispensed drug.

(m) Nothing contained in this section shall be construed as
preventing a pharmacist from refusing to fill or refill any prescription if in
the pharmacist's professional judgment and discretion such pharmacist is
of the opinion that it should not be filled or refilled.

New Sec. 7. (a) An automated dispensing system shall be under the supervision of a pharmacist licensed in Kansas, who may be retained on a part-time basis and who shall be responsible for recordkeeping and storage of all drugs and verifying and documenting each prescription drug prepared or dispensed by such system. 1 (b) The board shall adopt such rules and regulations relating to 2 automated dispensing systems as necessary for proper control and 3 operation.

4 5 (c) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

6 Sec. 8. K.S.A. 2015 Supp. 65-1642 is hereby amended to read as 7 follows: 65-1642. (a) Each pharmacy shall be equipped with proper 8 pharmaceutical utensils, in order that prescriptions can be properly filled and United States-pharmacopoeia pharmacopeia and national formulary 9 preparations properly compounded, and with proper sanitary appliances 10 which shall be kept in a clean and orderly manner. The board shall 11 12 prescribe the minimum of such professional and technical equipment which a pharmacy shall at all times possess. 13

14 (b) Each pharmacy shall keep a suitable book or file which records 15 every prescription order filled at the pharmacy and a medication profile 16 record system as provided under subsection (d). The book or file of 17 prescription orders shall be kept for a period of not less than five years. 18 The book or file of prescription orders shall at all times be open to 19 inspection by members of the board, the secretary of health and 20 environment, the duly authorized agents or employees of such board or 21 secretary and other proper authorities.

22 (c) (1) A medication profile record system shall be maintained in all 23 pharmacies for persons for whom prescriptions are dispensed. The 24 following information shall be recorded: (A) The name and address of the 25 patient for whom the medication is intended; (B) the prescriber's name, the 26 original date the prescription is dispensed and the number or designation 27 identifying the prescription; (C) the name, strength and quantity of the 28 drug dispensed and the name of the dispensing pharmacist; and (D) drug 29 allergies and sensitivities.

30 (2) Upon receipt of a prescription order, the pharmacist shall examine 31 the patient's medication profile record before dispensing the medication to 32 determine the possibility of a harmful drug interaction or reaction to 33 medication. Upon recognizing a potential harmful drug interaction or 34 reaction to the medication, the pharmacist shall take appropriate action to 35 avoid or minimize the problem which shall, if necessary, include 36 consultation with the prescriber with documentation of actions taken on 37 the prescription record.

38 (3) A medication profile record shall be maintained for a period of not39 less than five years from the date of the last entry in the record.

40 (4) All prescription drug orders communicated by way of electronic
41 transmission shall conform to federal and state laws and the provisions of
42 the board's rules and regulations.

43 (d) No registration shall be issued or continued for the conduct of a

pharmacy until or unless the provisions of this section have been complied
 with.

3 (e) Each pharmacy-sHall shall comply with the requirements of the 4 federal drug supply chain security act, 21 U.S.C. § 351 et seq.

5 Sec. 9. K.S.A. 2015 Supp. 65-1643 is hereby amended to read as 6 follows: 65-1643. It shall be unlawful:

7 (a) For any person to operate, maintain, open or establish any 8 pharmacy within this state without first having obtained a registration from 9 the board. Each application for registration of a pharmacy shall indicate the person or persons desiring the registration, including the pharmacist in 10 charge, as well as the location, including the street name and number, and 11 12 such other information as may be required by the board to establish the identity and exact location of the pharmacy. The issuance of a registration 13 14 for any pharmacy shall also have the effect of permitting such pharmacy to 15 operate as a retail dealer without requiring such pharmacy to obtain a retail 16 dealer's permit. On evidence satisfactory to the board: (1) That the 17 pharmacy for which the registration is sought will be conducted in full 18 compliance with the law and the rules and regulations of the board; (2) that 19 the location and appointments of the pharmacy are such that it can be 20 operated and maintained without endangering the public health or safety; 21 and (3) that the pharmacy will be under the supervision of a pharmacist, a 22 registration shall be issued to such persons as the board shall deem 23 qualified to conduct such a pharmacy.

24 (b) For any person to manufacture within this state any drugs except 25 under the personal and immediate supervision of a pharmacist or suchother person or persons as may be approved by the board after an-26 27 investigation and a determination by the board that such person or persons 28 is qualified by scientific or technical training or experience to perform-29 such duties of supervision as may be necessary to protect the public health 30 and safety; and no person shall manufacture any such drugs without first obtaining a registration so to do from the board. Such registration shall be 31 32 subject to such rules and regulations with respect to requirements,-33 sanitation and equipment, as the board may from time to time adopt for the 34 protection of public health and safety violate the federal drug supply chain 35 security act, 21 U.S.C. § 351 et seq.

(c) For any person to distribute at wholesale any drugs without first
obtaining a registration-so to do as a wholesale distributor from the board.

(d) For any person to-sell or offer for sale at public auction or private sale in a place where public auctions are conducted, any drugs without first having obtained a registration from the board so to do, and it shall be necessary to obtain the permission of the board in every instance where any of the products covered by this section are to be sold or offered for sale operate as a third-party logistics provider within this state without 1 *having first obtained a registration from the board.* 

2 (e) For any person to in any manner distribute or dispense samples of 3 any drugs without first having obtained a permit from the board so to do, 4 and it shall be necessary to obtain permission from the board in every 5 instance where the samples are to be distributed or dispensed. Nothing in 6 this subsection shall be held to regulate or in any manner interfere with the 7 furnishing of samples of drugs to duly licensed practitioners, to mid-level 8 practitioners, to pharmacists or to medical care facilities.

9 (f) Except as otherwise provided in this subsection (f), for any person 10 operating a store or place of business to sell, offer for sale or distribute any drugs to the public without first having obtained a registration or permit 11 12 from the board authorizing such person so to do. No retail dealer who sells 13 12 or fewer different nonprescription drug products shall be required to obtain a retail dealer's permit under the pharmacy act of the state of Kansas 14 or to pay a retail dealer new permit or permit renewal fee under such act. It 15 16 shall be lawful for a retail dealer who is the holder of a valid retail dealer's 17 permit issued by the board or for a retail dealer who sells 12 or fewer 18 different nonprescription drug products to sell and distribute 19 nonprescription drugs which are prepackaged, fully prepared by the manufacturer or distributor for use by the consumer and labeled in 20 21 accordance with the requirements of the state and federal food, drug and 22 cosmetic acts. Such nonprescription drugs shall not include: (1) A 23 controlled substance; (2) a prescription-only drug; or (3) a drug product 24 intended for human use by hypodermic injection; but such a retail dealer 25 shall not be authorized to display any of the words listed in-subsection (dd) 26 of K.S.A. 65-1626(uu), and amendments thereto, for the designation of a 27 pharmacy or drugstore.

(g) For any person to sell any drugs manufactured and sold only in
 the state of Kansas, unless the label and directions on such drugs shall first
 have been approved by the board.

(h) For any person to operate an institutional drug room without first
having obtained a registration to do so from the board. Such registration
shall be subject to the provisions of K.S.A. 65-1637a, and amendments
thereto, and any rules and regulations adopted pursuant thereto.

(i) For any person to operate a veterinary medical teaching hospital
pharmacy without first having obtained a registration to do so from the
board. Such registration shall be subject to the provisions of K.S.A. 651662, and amendments thereto, and any rules and regulations adopted
pursuant thereto.

40 (j) For any person to sell or distribute in a pharmacy a controlled 41 substance designated in subsection (c) or (f) of K.S.A. 65-4113(e) or (f), 42 and amendments thereto, unless:

43

(1) (A) Such controlled substance is sold or distributed by a licensed

pharmacist, a registered pharmacy technician or a pharmacy intern or clerk
 supervised by a licensed pharmacist;

(B) any person purchasing, receiving or otherwise acquiring any such 3 4 controlled substance produces a photo identification showing the date of birth of the person and signs a log and enters in the log, or allows the seller 5 6 to enter in the log, such person's address and the date and time of sale or 7 allows the seller to enter such information into an electronic logging 8 system pursuant to K.S.A. 2015 Supp. 65-16,102, and amendments 9 thereto. The log or database required by the board shall be available for 10 inspection during regular business hours to the board of pharmacy and any 11 law enforcement officer:

(C) the seller determines that the name entered in the log corresponds
to the name provided on such identification and that the date and time
entered are correct; and

(D) the seller enters in the log the name of the controlled substanceand the quantity sold; or

(2) there is a lawful prescription.

(k) For any pharmacy to allow customers to have direct access to any
controlled substance designated in subsection (c) or (f) of K.S.A. 654113(e) or (f), and amendments thereto. Such controlled substance shall be
placed behind the counter or stored in a locked cabinet that is located in an
area of the pharmacy to which customers do not have direct access.

(1) A seller who in good faith releases information in a log pursuant to
 subsection (j) to any law enforcement officer is immune from civil liability
 for such release unless the release constitutes gross negligence or
 intentional, wanton or willful misconduct.

(m) For any person to sell or lease or offer for sale or lease durable
medical equipment without first obtaining a registration from the board, in
accordance with rules and regulations adopted by the board, except that
this subsection shall not apply to:

31

17

(1) Sales not made in the regular course of the person's business; or

32 (2) sales by charitable organizations exempt from federal income33 taxation pursuant to the internal revenue code of 1986, as amended.

(n) For any person to operate as an outsourcing facility within this
state, or operate as an outsourcing facility outside of Kansas and ship,
mail or deliver drugs into this state, without having first obtained a
registration from the board.

(0) For any person to operate an automated dispensing system within
 this state without having first obtained a registration from the board.

40 Sec. 10. K.S.A. 2015 Supp. 65-1645 is hereby amended to read as 41 follows: 65-1645. (a) Application for registrations or permits under K.S.A. 42 65-1643, and amendments thereto, shall be made on a form prescribed and 43 furnished by the board. Applications for registration—to distribute at-

1 wholesale any drugs shall contain such information as may be required by 2 the board in accordance with the provisions of K.S.A. 65-1655, and amendments thereto, and sections 13 and 14, and amendments thereto. 3 The application shall be accompanied by the fee prescribed by the board 4 under the provisions of this section. When such application and fees are 5 6 received by the executive secretary of the board on or before the due date, 7 such application shall have the effect of temporarily renewing the 8 applicant's registration or permit until actual issuance or denial of the renewal. However, if at the time of filing a proceeding is pending before 9 10 the board which may result in the suspension, probation, revocation or denial of the applicant's registration or permit, the board may declare, by 11 12 emergency order, that such application for renewal shall not have the effect of temporarily renewing such applicant's registration or permit. Separate 13 14 applications shall be made and separate registrations or permits issued for 15 each separate place at which is carried on any of the operations for which a 16 registration or permit is required by K.S.A. 65-1643, and amendments 17 thereto

(b) The nonrefundable fees required for the issuing of the licenses,
registrations or permits under the pharmacy act of the state of Kansas shall
be fixed by the board as herein provided, subject to the following:

(1) Pharmacy, new registration not more than \$150, renewal not more
than \$125;

(2) pharmacist, new license by examination not more than \$350;

24 (3) pharmacist, reinstatement application fee not more than \$250;

25 (4) pharmacist, biennial renewal fee not more than \$200;

26 (5) pharmacist, evaluation fee not more than \$250;

27 (6) pharmacist, reciprocal licensure fee not more than \$250;

(7) pharmacist, penalty fee, not more than \$500;

(8) manufacturer, new registration not more than \$500, renewal notmore than \$400;

31 (9) wholesaler, wholesale distributor new registration not more than 32 \$500, renewal not more than \$400, except that a wholesaler wholesale 33 distributor dealing exclusively in nonprescription drugs, manufacturing, distributing or dispensing of which does not require 34 35 registration under the uniform controlled substances act, shall be assessed 36 a fee for registration and reregistration not to exceed \$50;

37

23

28

(10) special auction not more than \$50;

38 (11) samples distribution not more than \$50, renewal not more than
39 \$50;

40 (12) institutional drug room, new registration not more than \$40, 41 renewal not more than \$35;

42 (13) retail dealer selling more than 12 different nonprescription drug
43 products, new permit not more than \$12, renewal not more than \$12;

1 (14) certification of grades for each applicant for examination and 2 registration not more than \$25;

- 3 (15) veterinary medical teaching hospital pharmacy, new registration
  4 not more than \$40, renewal not more than \$35; or
- 5 (16) durable medical equipment registration fee, not more than \$300, 6 renewal not more than \$300;
- 7 (17) third-party logistics provider, new registration not more than 8 \$500, renewal not more than \$400, except that a third-party logistics 9 provider dealing exclusively in nonprescription drugs, the manufacturing, 10 distributing or dispensing of which does not require registration under the 11 uniform controlled substances act, shall be assessed a fee for registration 12 and re-registration not to exceed \$50;

(18) outsourcing facility, new registration not more than \$500,
renewal not more than \$400;

- 15 (19) repackager, new registration not more than \$500, renewal not 16 more than \$400; or
- (20) automated dispensing system registration fee, not more than
  \$40, renewal not more than \$35.
- (c) For the purpose of fixing fees, the board may establish classes of
  retail dealers' permits for retail dealers selling more than 12 different
  nonprescription drug products, and the board may fix a different fee for
  each such class of permit.
- (d) The board shall determine annually the amount necessary to carry out and enforce the provisions of this act for the next ensuing fiscal year and shall fix by rules and regulations the fees authorized for such year at the sum deemed necessary for such purposes. The fees fixed by the board under this section immediately prior to the effective date of this act shall continue in effect until different fees are fixed by the board by rules and regulations as provided under this section.

30 (e) The board may deny renewal of any registration or permit 31 required by K.S.A. 65-1643, and amendments thereto, on any ground 32 which would authorize the board to suspend, revoke or place on probation 33 a registration or permit previously granted pursuant to the provisions of 34 K.S.A. 65-1643, and amendments thereto. Registrations and permits issued 35 under the provisions of K.S.A. 65-1643 and 65-1644, and amendments 36 thereto, shall be conspicuously displayed in the place for which the 37 registration or permit was granted. Such registrations or permits shall not 38 be transferable. All such registrations and permits shall expire every year. 39 The expiration date shall be established by rules and regulations adopted 40 by the board. All registrations and permits shall be renewed annually. 41 Notice of renewal of registrations and permits shall be-mailed sent by the 42 board to each registrant or permittee at least 30 days prior to expiration of 43 the registration or permit. If application for renewal is not made prior to

expiration, the existing registration or permit shall lapse and become null and void on the date of its expiration, and no new registration or permit shall be granted except upon payment of the required renewal fee plus a penalty equal to the renewal fee. Failure of any registrant or permittee to receive such notice of renewal shall not relieve the registrant or permittee from the penalty hereby imposed if the renewal is not made as prescribed.

7 (f) In each case in which a license of a pharmacist is issued or 8 renewed for a period of time less than two years, the board shall prorate to 9 the nearest whole month the license or renewal fee established pursuant to 10 this section.

(g) The board may require that fees paid for any examination under
the pharmacy act of the state of Kansas be paid directly to the examination
service by the person taking the examination.

14 Sec. 11. K.S.A. 65-1648 is hereby amended to read as follows: 65-1648. (a) Any medical care facility pharmacy registered by the board may 15 16 keep drugs in such facility and may supply drugs to its inpatients and outpatients. Distribution and control of prescription medications in a 17 medical care facility pharmacy shall be under the supervision of a 18 19 pharmacist in charge. A designated registered nurse or nurses or a licensed 20 physician assistant approved by the pharmacist in charge and under the 21 supervision of the pharmacist in charge shall be in charge of the 22 distribution and control of drugs of a medical care facility pharmacy when 23 a pharmacist is not on the premises. Drugs supplied to outpatients when a 24 pharmacist is not on the premises shall be limited to the quantity necessary 25 until a prescription can be filled.

(b) Nothing contained in this act shall be construed as prohibiting an 26 27 adult care home which utilizes the services of a pharmacist, from 28 maintaining an emergency medication kit approved by the adult care 29 home's medical staff composed of a duly licensed practitioner and a 30 pharmacist. The emergency medication kit shall be used only in 31 emergency cases under the supervision and direction of a duly licensed 32 practitioner, and a pharmacist shall have supervisory responsibility of 33 maintaining said emergency medication kit.

34 (c) Every adult care home which maintains an emergency medication35 kit under subsection (b) shall comply with the following requirements:

(1) Drugs in an emergency medication kit shall be maintained under
the control of the pharmacist in charge of the pharmacy from which the kit
came until administered to the patient upon the proper order of a
practitioner.

40 (2) Drugs contained within the emergency medication kit may
41 include controlled substances, but in such case a pharmaceutical services
42 committee shall be responsible for specifically limiting the type and
43 quantity of controlled substance to be placed in each emergency kit.

1 (3) Administration of controlled substances contained within the emergency medication kit shall be in compliance with the provisions of the 2 3 uniform controlled substances act.

4

(4) The consultant pharmacist of the adult care home shall be 5 responsible for developing procedures, proper control and accountability 6 for the emergency medication kit and shall maintain complete and accurate 7 records of the controlled substances, if any, placed in the emergency kit. 8 Periodic physical inventory of the kit shall be required.

9 (d) (1) The state department of health and environment, any county, 10 city-county or multicounty health department, indigent health care clinic, federally qualified health center and any private not-for-profit family 11 12 planning clinic, when registered by the board, may keep drugs for the purpose of distributing drugs to patients being treated by that health 13 14 department, indigent health care clinic, federally qualified health center or family planning clinic. Distribution and control of prescription 15 16 medications in a health department, indigent health care clinic, federally 17 qualified health center or family planning clinic shall be under the 18 supervision of a pharmacist in charge. A designated registered nurse or 19 nurses or a licensed physician assistant approved by the pharmacist in 20 charge shall be in charge of distribution and control of drugs in the health 21 department, indigent health care clinic, federally gualified health center or 22 family planning clinic under the supervision of the pharmacist in charge 23 when a pharmacist is not on the premises. Drugs supplied to patients when 24 a pharmacist is not on the premises shall be limited to the quantity necessary to complete a course of treatment as ordered by the practitioner 25 26 supervising such treatment.

27 (2) The board shall adopt rules and regulations relating to specific 28 drugs to be used, to recordkeeping and to storage of drugs by a health 29 department, indigent health care clinic, federally qualified health center or 30 family planning clinic as are necessary for proper control of drugs.

31 (3) Any medical care facility pharmacy registered by the board shall 32 comply with the applicable requirements of the federal drug supply chain 33 security act, 21 U.S.C. § 351 et seq.

34 Sec. 12. K.S.A. 2015 Supp. 65-1655 is hereby amended to read as 35 follows: 65-1655. (a) The board shall require an applicant for registration 36 to distribute at as a wholesale any drugs distributor under K.S.A. 65-1643, 37 and amendments thereto, or an applicant for renewal of such a registration, 38 to provide the following information:

39 (1) The name, full business address and telephone number of the 40 applicant; 41

(2) all trade or business names used by the applicant;

42 (3) addresses, telephone numbers, and the names of contact persons 43 for all facilities used by the applicant for the storage, handling and

1 distribution of prescription drugs;

(4) the type of ownership or operation of the applicant;

3 (5) the name of the owner or operator, or both, of the applicant, 4 including:

5

2

(A) If a person, the name of the person;

6 (B) if a partnership, the name of each partner, and the name of the 7 partnership;

8 (C) if a corporation, the name and title of each corporate officer and 9 director, the corporate names and the name of the state of incorporation;

10 (D) if a sole proprietorship, the full name of the sole proprietor and 11 the name of the business entity; and

(6) such other information as the board deems appropriate. Changes
in any information in this subsection (a) shall be submitted to the board as
required by such board.

(b) In reviewing the qualifications for applicants for initial
 registration or renewal of registration-to distribute at as a wholesale-any
 drugs distributor, the board shall consider the following factors:

(1) Any convictions of the applicant under any federal, state or local
laws relating to drug samples, wholesale or retail drug distribution or
distribution of controlled substances;

(2) any felony convictions of the applicant under federal or statelaws;

(3) the applicant's past experience in the manufacture or distribution
 of prescription drugs, including controlled substances;

(4) the furnishing by the applicant of false or fraudulent material in
 any application made in connection with drug manufacturing or
 distribution;

(5) suspension or revocation by federal, state or local government of
 any license or registration currently or previously held by the applicant for
 the manufacture or distribution of any drugs, including controlled
 substances;

32 (6) compliance with registration requirements under previously33 granted registrations, if any;

(7) compliance with requirements to maintain or make available to
the board or to federal state or local law enforcement officials those
records required by federal food, drug and cosmetic act, and rules and
regulations adopted pursuant thereto; and

(8) any other factors or qualifications the board considers relevant toand consistent with the public health and safety.

40 (c) After consideration of the qualifications for applicants for 41 registration-to distribute at *as a* wholesale any drugs *distributor*, the board 42 may deny an initial application for registration or application for renewal 43 of a registration if the board determines that the granting of such registration would not be in the public interest. The authority of the board
 under this subsection to deny a registration-to distribute at as a wholesale
 any drugs distributor shall be in addition to the authority of the board
 under-subsection (e) of K.S.A. 65-1627(e), and amendments thereto, or
 subsection (c) of K.S.A. 65-1645(e), and amendments thereto.

6 (d) The board by rules and regulations shall require that personnel 7 employed by persons registered to distribute at *as a* wholesale any drugs 8 *distributor* have appropriate education or experience, or both, to assume 9 responsibility for positions related to compliance with state registration 10 requirements.

(e) The board by rules and regulations may implement this section to
 conform to any requirements of the federal-prescription drug marketing act
 of 1987 drug supply chain security act-(, 21 U.S.C. §-321 351 et seq.), in
 effect on the effective date of this act.

(f) Each facility that engages in wholesale distribution must undergo 15 16 an inspection by the board or a third party recognized by the board to 17 inspect-and accredit wholesale distributors for the purpose of inspecting 18 the wholesale distribution operations prior to initial registration and 19 periodically thereafter in accordance with a schedule to be determined by 20 the board but not less than once every three years. The board shall have the 21 authority to waive registration requirements for wholesale distributors that 22 are accredited by an accrediting agency approved by the board. The board 23 shall adopt rules and regulations to establish standards and requirements for the issuance and maintenance of a wholesale distributor registration, 24 25 including inspections of wholesale distributor facilities domiciled in the 26 state.

(1) Individual or third party inspectors must demonstrate to the board that they have received training or demonstrate familiarity with the inspection standards. Evidence such as a letter of certification from a training program, notice from the inspector's employing third party organization or other means recognized by the board shall be accepted as meeting the requirement.

(2) The board may register a wholesale distributor that is licensed orregistered under the laws of another state if:

35 (A) The requirements of that state are deemed by the board to be 36 substantially equivalent; or

(B) the applicant is inspected and accredited by a third party
recognized and approved by the board.

(g) A person licensed or approved by the federal food and drugadministration *FDA* to engage in the manufacture of drugs or devices
engaged in wholesale distribution need only satisfy the minimum federal
requirements for licensure provided in federal food and drugadministration *FDA* regulations 21 C.F.R. Part 205 to provide wholesale

distribution services. 1

- 2 (h) The board by rule and regulation shall establish standards and 3 requirements for the issuance and maintenance of a wholesale distributor 4 registration, including, but not limited to, requirements regarding the 5 following:
- 6 (1) An application and renewal fee;
- 7 (2) a surety bond;
- 8 (3) registration and periodic inspections;
- (4) certification of a designated representative; 9
- (5) designation of a registered agent; 10
- (6) storage of drugs and devices; 11
- (7) handling, transportation and shipment of drugs and devices; 12
- 13 (8) security;
- (9) examination of drugs and devices and treatment of those found to 14 be unacceptable as defined by the board; 15
- 16 (10) due diligence regarding other wholesale distributors trading 17 partners:
- 18 (11) creation and maintenance of records, including transaction 19 records:-and
- 20 (12) procedures for operation; and
- 21 (13) procedures for compliance with the requirements of the federal 22 drug supply chain security act, 21 U.S.C. § 351 et seq.
- 23 (i) This section shall be part of and supplemental to the pharmacy act of the state of Kansas. 24
- 25 New Sec. 13. (a) The board shall require an applicant for registration to operate as a third-party logistics provider under K.S.A. 65-1643, and 26 amendments thereto, or an applicant for renewal of such a registration, to 27 28 provide the following information:
- (1) The name, full business address and telephone number of the 29 30 applicant;
- 31
  - (2) all trade or business names used by the applicant;
- (3) addresses, telephone numbers, and the names of contact persons 32 33 for all facilities used by the applicant for the storage, handling and 34 distribution of prescription drugs;
- 35

(4) the type of ownership or operation of the applicant;

- (5) the name of the owner or operator, or both, of the applicant, 36 37 including: 38
  - (A) If a person, the name of the person;
- 39 (B) if a partnership, the name of each partner, and the name of the 40 partnership;
- (C) if a corporation, the name and title of each corporate officer and 41 42 director, the corporate names and the name of the state of incorporation;
- 43 (D) if a sole proprietorship, the full name of the sole proprietor and

1 the name of the business entity; and

2 (6) such other information as the board deems appropriate. Changes
3 in any information in this subsection (a) shall be submitted to the board as
4 required by such board.

5 (b) In reviewing the qualifications for applicants for initial 6 registration or renewal of registration to operate as a third-party logistics 7 provider, the board shall consider the following factors:

8 (1) Any convictions of the applicant under any federal, state or local 9 laws relating to drug samples, wholesale or retail drug distribution or 10 distribution of controlled substances;

(2) any felony convictions of the applicant under federal or statelaws;

(3) the applicant's past experience in the manufacture or distributionof prescription drugs, including controlled substances;

15 (4) the furnishing by the applicant of false or fraudulent material in 16 any application made in connection with drug manufacturing or 17 distribution;

(5) suspension or revocation by federal, state or local government of
 any license or registration currently or previously held by the applicant for
 the manufacture or distribution of any drugs, including controlled
 substances;

(6) compliance with registration requirements under previouslygranted registrations, if any;

(7) compliance with requirements to maintain or make available to
the board or to federal state or local law enforcement officials those
records required by the federal food, drug and cosmetic act, and rules and
regulations adopted pursuant thereto; and

(8) any other factors or qualifications the board considers relevant toand consistent with the public health and safety.

(c) After consideration of the qualifications for applicants for 30 31 registration to operate as a third-party logistics provider, the board may 32 deny an initial application for registration or application for renewal of a 33 registration if the board determines that the granting of such registration 34 would not be in the public interest. The authority of the board under this 35 subsection to deny a registration to operate a third-party logistics provider 36 shall be in addition to the authority of the board under K.S.A. 65-1627(e) 37 or 65-1645(e), and amendments thereto.

(d) The board by rules and regulations shall require that personnel
employed by persons registered to operate as a third-party logistics
provider have appropriate education or experience, or both, to assume
responsibility for positions related to compliance with state registration
requirements.

43

(e) The board by rules and regulations may implement this section to

conform to any requirements of the federal drug supply chain security act. 1 2 21 U.S.C. § 351 et seq., in effect on the effective date of this act.

3 (f) Each facility that operates as a third-party logistics provider must undergo an inspection by the board or a third party recognized by the 4 board to inspect third-party logistics provider operations prior to initial 5 6 registration and periodically thereafter in accordance with a schedule to be 7 determined by the board, but not less than once every three years. The 8 board shall adopt rules and regulations to establish standards and requirements for the issuance and maintenance of a third-party logistics 9 provider registration, including inspections of third-party logistics provider 10 facilities domiciled in the state 11

12 (1) Individual or third-party inspectors must demonstrate to the board that they have received training or demonstrate familiarity with the 13 inspection standards. Evidence, such as a letter of certification from a 14 15 training program, notice from the inspector's employing third-party 16 organization or other means recognized by the board shall be accepted as 17 meeting the requirement.

18 (2) The board may register a third-party logistics provider that is 19 licensed or registered under the laws of another state if:

20 (A) The requirements of that state are deemed by the board to be 21 substantially equivalent; or

22 (B) the applicant is inspected by a third party recognized and 23 approved by the board.

24 (g) A person licensed or approved by the FDA to engage in the 25 manufacture of drugs or devices engaged in third-party logistics need only satisfy the minimum federal requirements for licensure provided in FDA 26 27 regulations 21 C.F.R. Part 205 to provide third-party logistics services.

28 (h) The board by rule and regulation shall establish standards and 29 requirements for the issuance and maintenance of a third-party logistics provider registration, including, but not limited to, requirements regarding 30 31 the following:

- 32 (1) An application and renewal fee;
- 33 (2) a surety bond;

34 (3) registration and periodic inspections;

- 35 (4) certification of a designated representative;
- 36 (5) designation of a registered agent;
- 37 (6) storage of drugs and devices;
- 38 (7) handling, transportation and shipment of drugs and devices;
- 39 (8) security;
- 40 (9) examination of drugs and devices and treatment of those found to 41 be unacceptable as defined by the board;
- due diligence regarding other trading partners; 42 (10)
- 43 (11) creation and maintenance of records, including transaction

1 records	;
-----------	---

2

(12) procedures for operation; and

3 (13) procedures for compliance with the requirements of the federal 4 drug supply chain security act, 21 U.S.C. § 351 et seq.

5 (i) This section shall be part of and supplemental to the pharmacy act 6 of the state of Kansas.

New Sec. 14. (a) The board shall require an applicant for registration
as an outsourcing facility under K.S.A. 65-1643, and amendments thereto,
or an applicant for renewal of such a registration, to provide the following
information:

11 (1) The name, full business address and telephone number of the 12 applicant;

13 14

17

(2) all trade or business names used by the applicant;

(3) the type of ownership or operation of the applicant;

15 (4) the name of the owner or operator, or both, of the applicant,16 including:

(A) If a person, the name of the person;

(B) if a partnership, the name of each partner, and the name of thepartnership;

20 (C) if a corporation, the name and title of each corporate officer and 21 director, the corporate names and the name of the state of incorporation;

(D) if a sole proprietorship, the full name of the sole proprietor andthe name of the business entity;

(5) a copy of the valid FDA registration as an outsourcing facility as
 required by 21 U.S.C. § 353b;

(6) the name and license number of the pharmacist who is designatedas the pharmacist-in-charge of the outsourcing facility;

(7) a copy of a current inspection report resulting from an FDA inspection that indicates compliance with the requirements of the federal food, drug and cosmetic act, including guidance documents and current good manufacturing practices established by the FDA, or if no FDA inspection has been conducted within the prior two-year period, the outsourcing facility must undergo an inspection pursuant to subsection (e); and

35

(8) such other information as the board deems appropriate.

Changes in any information in this subsection (a) shall be submitted to the board as required by such board.

(b) In reviewing the qualifications for applicants for initial
 registration or renewal of registration as an outsourcing facility, the board
 shall consider the following factors:

41 (1) Any convictions of the applicant under any federal, state or local
42 laws relating to drug samples, wholesale or retail drug distribution or
43 distribution of controlled substances;

38

(2) any felony convictions of the applicant under federal or state 1 2 laws;

3 (3) the applicant's past experience in the manufacture or distribution 4 of prescription drugs, including controlled substances;

5

(4) the furnishing by the applicant of false or fraudulent material in 6 any application made in connection with drug manufacturing or 7 distribution;

8 (5) suspension or revocation by federal, state or local government of 9 any license or registration currently or previously held by the applicant for the manufacture or distribution of any drugs, including controlled 10 11 substances.

(6) compliance with registration requirements under previously 12 13 granted registrations, if any;

14 (7) compliance with requirements to maintain or make available to the board or to federal state or local law enforcement officials those 15 16 records required by the federal food, drug and cosmetic act, and rules and 17 regulations adopted pursuant thereto; and

(8) any other factors or qualifications the board considers relevant to 18 19 and consistent with the public health and safety.

(c) After consideration of the qualifications for applicants for 20 21 registration as an outsourcing facility, the board may deny an initial 22 application for registration or application for renewal of a registration if 23 the board determines that the granting of such registration would not be in the public interest. The authority of the board under this subsection to deny 24 25 a registration to operate as an outsourcing facility shall be in addition to 26 the authority of the board under K.S.A. 65-1627(e) or 65-1645(e), and 27 amendments thereto.

28 (d) The board by rules and regulations shall require that personnel employed by persons registered as an outsourcing facility have appropriate 29 education or experience, or both, to assume responsibility for positions 30 31 related to compliance with state registration requirements.

32 (e) Each outsourcing facility must undergo an inspection by the board 33 or a third party recognized by the board for the purpose of inspecting 34 operations prior to initial registration and periodically thereafter in 35 accordance with a schedule to be determined by the board, but not less 36 than once every three years. The board shall adopt rules and regulations to 37 establish standards and requirements for the issuance and maintenance of 38 an outsourcing facility registration, including inspections of facilities 39 domiciled in the state.

40 The board by rule and regulation shall establish standards and (f) 41 requirements for the issuance and maintenance of an outsourcing facility 42 registration, including, but not limited to, requirements regarding the 43 following:

- 1 (1) An application and renewal fee;
- 2 (2) a surety bond;
- 3 (3) registration and periodic inspections;
- 4 (4) certification of a designated representative;
- 5 (5) designation of a registered agent;
- 6 (6) storage of drugs and devices;
- 7 (7) handling, transportation and shipment of drugs and devices;
- 8 (8) security;
- 9 (9) examination of drugs and devices and treatment of those found to 10 be unacceptable as defined by the board;
  - (10) due diligence regarding other trading partners;
- (11) creation and maintenance of records, including transactionrecords; and
- 14

11

- (12) procedures for operation.
- (g) Notwithstanding any other provision, no outsourcing facility may
  distribute or dispense any drug to any person pursuant to a prescription
  unless it is also registered as a pharmacy in this state and meets all other
  applicable requirements of federal and state law.
- (h) This section shall be part of and supplemental to the pharmacy actof the state of Kansas.
- 21 Sec. 15. K.S.A. 2015 Supp. 65-1663 is hereby amended to read as 22 follows: 65-1663. (a) It shall be unlawful for any person to function as a 23 pharmacy technician in this state unless such person is registered with the 24 board as a pharmacy technician. Every person registered as a pharmacy 25 technician shall have graduated from an accredited high school or its equivalent, obtained a graduate equivalent diploma (GED), or be enrolled 26 27 and in good standing in a high-school education program. Every person 28 registered as a pharmacy technician shall pass one or more examinations 29 identified and approved by the board within the period or periods of time specified by the board after becoming registered. The board shall adopt 30 31 rules and regulations identifying the required examinations, when they 32 must be passed and establishing the criteria for the required examinations 33 and passing scores. The board may include as a required examination any 34 national pharmacy technician certification examination. The board shall 35 adopt rules and regulations restricting the tasks a pharmacy technician 36 may perform prior to passing any required examinations.
- (b) All applications for registration shall be made on a form to be
  prescribed and furnished by the board. Each application for registration
  shall be accompanied by a registration fee fixed by the board by rule and
  regulation not to exceed \$50.
- 41 (c) The board shall take into consideration any felony conviction of
   42 an applicant, but such conviction shall not automatically operate as a bar to
   43 registration.

1 (d) Except as otherwise provided in this subsection, each pharmacy 2 technician registration issued by the board shall expire every two years. 3 The expiration date shall be established by rules and regulations adopted 4 by the board. To provide for a system of biennial renewal of pharmacy 5 technician registrations, the board may provide by rules and regulations 6 that registrations issued or renewed may expire less than two years from 7 the date of issuance or renewal. Each applicant for renewal of a pharmacy 8 technician registration shall be made on a form prescribed and furnished 9 by the board and shall be accompanied by a renewal fee fixed by the board 10 by rule and regulation not to exceed \$25. Pharmacy technician registration renewal fees may be prorated for registration periods which are less than 11 12 biennial in accordance with rules and regulations of the board. Except as 13 otherwise provided in this subsection, the application for registration 14 renewal, when accompanied by the renewal fee and evidence satisfactory 15 to the board that the person has successfully complied with the rules and 16 regulations of the board establishing the requirements for a program of 17 continuing pharmacy technician education and received by the executive 18 secretary-of the board on or before the date of expiration of the 19 registration, shall have the effect of temporarily renewing the applicant's 20 registration until actual issuance or denial of the renewal registration. If at 21 the time of filing a proceeding is pending before the board which may 22 result in the suspension, probation, revocation or denial of the applicant's 23 registration, the board may by emergency order declare that the application 24 for renewal shall not have the effect of temporarily renewing such 25 applicant's registration. If the renewal fee is not paid prior to the expiration 26 date of the renewal year, the registration is void.

(e) Continuing pharmacy technician education requirements shall be
fixed by the board at not more than 20 clock hours biennially of a program
of continuing education approved by the board. Continuing education
hours may be prorated for licensure periods which are less than biennial
in accordance with rules and regulations of the board.

*(f)* (1) The board may limit, suspend or revoke a registration or deny an application for issuance or renewal of any registration as a pharmacy technician on any ground, which would authorize the board to take action against the license of a pharmacist under K.S.A. 65-1627, and amendments thereto.

37 (2) The board may require a physical or mental examination, or both,38 of a person applying for or registered as a pharmacy technician.

39 (3) The board may temporarily suspend or temporarily limit the registration of any pharmacy technician in accordance with the emergency adjudicative proceedings under the Kansas administrative procedure act if the board determines that there is cause to believe that grounds exist for disciplinary action under this section against the registrant and that the registrant's continuation of pharmacy technician functions would constitute
 an imminent danger to the public health and safety.

3 (4) Proceedings under this section shall be subject to the Kansas 4 administrative procedure act.

5 (f) (g) Every registered pharmacy technician, within 30 days of 6 obtaining new employment *or ceasing employment as a pharmacy* 7 *technician*, shall-furnish *notify* the board's executive secretary-notice of the 8 name and address of the new employer *or cessation of employment*.

9 (h) Every pharmacist technician who changes residential address, 10 email address or legal name shall, within 30 days thereof, notify the 11 secretary of such change on a form prescribed and furnished by the board.

12 (g) (i) Each pharmacy shall at all times maintain a list of the names of pharmacy technicians employed by the pharmacy. A pharmacy technician 13 14 shall work under the direct supervision and control of a pharmacist, and 15 while on duty, shall wear a name badge or similar identification with the 16 pharmacy technician's name and designation as a pharmacy technician. It 17 shall be the responsibility of the supervising pharmacist to determine that 18 the pharmacy technician is in compliance with the applicable rules and 19 regulations of the board, and the supervising pharmacist shall be 20 responsible for the acts and omissions of the pharmacy technician in the 21 performance of the pharmacy technician's duties. The ratio of pharmacy 22 technicians to pharmacists in the prescription area of a pharmacy shall be 23 prescribed by the board by rule and regulation. Any change in the ratio of 24 pharmacy technicians to pharmacists in the prescription area of the 25 pharmacy must be adopted by a vote of no less than six members of the 26 board.

(h) (j) A person holding aEvery registered pharmacy technician
 registration shall display-such the current registration in that part of the
 place of business in which such person is engaged in pharmacy technician
 activities.

(k) Every pharmacy technician registered after July 1, 2016, shall be
 required to pass a certified pharmacy technician examination approved by
 the board.

(i) (l) The board shall adopt such rules and regulations as are
 necessary to ensure that pharmacy technicians are adequately trained as to
 the nature and scope of their lawful duties.

(i) (m) The board may adopt rules and regulations as may be necessary to carry out the purposes and enforce the provisions of this act.

39 (k) (n) This section shall be part of and supplemental to the pharmacy 40 act of the state of Kansas.

41 Sec. 16. K.S.A. 2015 Supp. 65-1676 is hereby amended to read as 42 follows: 65-1676. (a) It shall be unlawful for any person to function as a 43 pharmacist intern in this state unless such person is registered with the 1 board as a pharmacist intern.

2 (b) All applications for registration shall be made on a form to be 3 prescribed and furnished by the board. Each application for registration 4 shall be accompanied by a registration fee fixed by the board by rule and 5 regulation not to exceed \$25.

6 (c) Each pharmacist intern registration issued by the board shall 7 expire six years from the date of issuance.

8 (d) (1) The board may limit, suspend or revoke a registration or deny 9 an application for issuance or renewal of any registration as a pharmacist 10 intern on any ground that would authorize the board to take action against 11 the license of a pharmacist under K.S.A. 65-1627, and amendments 12 thereto.

13 (2) The board may temporarily suspend or temporarily limit the 14 registration of any pharmacist intern in accordance with the emergency 15 adjudicative proceedings under the Kansas administrative procedure act, if 16 the board determines that there is cause to believe that grounds exist for 17 disciplinary action under this section against the registrant and that the 18 registrant's continuation of pharmacist intern functions would constitute an 19 imminent danger to the public health and safety.

20 (3) Proceedings under this section shall be subject to the Kansas21 administrative procedure act.

(e) Every registered pharmacist intern, within 30 days of obtaining
new employment, shall furnish the board's executive secretary notice of
the name and address of the new employer.

(f) Every pharmacist intern who changes residential address, email
address or legal name shall, within 30 days thereof, notify the secretary of
such change on a form prescribed and furnished by the board.

28 (g) Each pharmacy shall at all times maintain a list of the names of 29 pharmacist interns employed by the pharmacy. A pharmacist intern shall 30 work under the direct supervision and control of a pharmacist. It shall be 31 the responsibility of the supervising pharmacist to determine that the pharmacist intern is in compliance with the applicable rules and 32 33 regulations of the board, and the supervising pharmacist shall be 34 responsible for the acts and omissions of the pharmacist intern in the 35 performance of the pharmacist intern's duties.

36 (g) (h) A person holding a pharmacist intern registration shall display 37 such registration in that part of the place of business in which such person 38 is engaged in pharmacist intern activities.

39 (h) (i) The board shall adopt such rules and regulations as are 40 necessary to ensure that pharmacist interns are adequately trained as to the 41 nature and scope of their lawful duties. The board may adopt rules and 42 regulations as may be necessary to carry out the purposes of and enforce 43 the provisions of this section. 1 (i) (j) This section shall be part of and supplemental to the pharmacy 2 act of the state of Kansas.

3 New Sec. 17. (a) The board shall adopt rules and regulations 4 governing proper compounding practices and distribution of compounded 5 drugs by pharmacists and pharmacies.

6 (b) This section shall be part of and supplemental to the pharmacy act 7 of the state of Kansas.

8 Sec. 18. K.S.A. 65-669 is hereby amended to read as follows: 65-669.
9 A drug or device shall be deemed to be misbranded:

10

(a) If its labeling is false or misleading in any particular.

(b) If in package form unless it bears a label containing: (1) The name 11 12 and place of business of the manufacturer, the packer or the distributor, 13 except that in the case of a prescription drug it shall bear the name and place of business of the person responsible for the production of the 14 15 finished dosage form of the drug, the packer and the distributor; except 16 that nothing in-clause paragraph (1) of this paragraph subsection shall be 17 construed to apply to wholesalers and the requirement of clause paragraph 18 (1) shall be satisfied by stating such information on the label of the drug 19 and filing a statement with such information with the secretary which shall 20 be made available by the secretary on request to local, public and private 21 health agencies, poison control centers, licentiates of the healing arts, the 22 state board of pharmacy, consumers and others to promote the purposes of 23 this act; in no event, however, shall the label contain less information than 24 required under federal law; and (2) an accurate statement of the quantity of 25 the contents in terms of weight, measure, or numerical count, except that 26 under-clause paragraph (2) of this-paragraph subsection reasonable 27 variations shall be permitted and exemptions as to small packages shall be 28 allowed, in accordance with regulations prescribed by the secretary, or 29 issued under the federal act.

(c) If any word, statement, or other information required by or under
authority of this act to appear on the label or labeling is not prominently
placed thereon with such conspicuousness—(, as compared with other
words, statements, designs or devices, in the labeling), and in such terms
as to render it likely to be read and understood by the ordinary individual
under customary conditions of purchase and use.

36 (d) If it is for use by man and contains any quantity of narcotic or 37 hypnotic substance alpha-eucaine, barbituric acid, beta-eucaine, bromal, 38 cannabis, carbromal, chloral, coca, cocaine, codeine, heroin, marijuana, 39 morphine, opium, paraldehyde, peyote, or sulphonmethane, or any 40 chemical derivative of such substance, which derivative has been by the 41 secretary after investigation, found to be, and by regulations under this act, 42 or by regulations issued pursuant to 21 U.S.C. § 352 (d), designated as, 43 habit forming, unless its label bears the name and quantity or proportion of

such substance or derivative and in juxtaposition therewith the statement 1 2 "warning-may be habit forming."

3 (e) (1) If it is a drug, unless its label bears, to the exclusion of any 4 other nonproprietary name-(, except the applicable systematic chemical 5 name or the chemical formula); (i)(A) The established name (, as defined in-subparagraph paragraph (2)), of the drug, if such there be; and (ii)(B)6 7 in case it is fabricated from two or more ingredients, the established name 8 of each active ingredient, including the kind and quantity of proportion of 9 any alcohol, and also including, whether active or not, the established name and quantity or proportion of any bromides, ether, chloroform, 10 acetanilid, acetphenetidin, amidopyrine, antipyrine, atropine, hyoscine, 11 12 hyoscyamine, arsenic, digitalis, digitalis glucosides, mercury, ouabain, strophanthin, strychnine, thyroid, or any derivative or preparation of any 13 such substances, contained therein. The requirements for stating the 14 15 quantity of the active ingredients, other than the quantity of those specifically named in this paragraph, shall apply only to prescription 16 17 drugs. To the extent that compliance with the requirements of clause (ii) 18 paragraph (B) of this-subparagraph subsection is impracticable, 19 exemptions shall be allowed under regulations promulgated by the 20 secretary, or under the federal act.

21 (2) As used in this-paragraph subsection (e), the term "established 22 name," with respect to a drug or ingredient thereof, means: (A) The 23 applicable official name designated pursuant to 21 U.S.C. § 358, or; (B) if 24 there is no such name and such drug, or such ingredient, is an article 25 recognized in an official compendium, then the official title thereof in such 26 compendium; or (C) if neither-elause subparagraph (A) nor-elause-27 subparagraph (B) of this-subparagraph paragraph applies, then the 28 common or usual name, if any, of such drug or of such ingredient. Where 29 elause subparagraph (B) of this-subparagraph paragraph applies to an 30 article recognized in the United States-pharmacopoeia pharmacopeia and 31 in the homeopathic-pharmacopoeia pharmacopeia under different official 32 titles, the official title used in the United States-pharmacopocia-33 pharmcopeia shall apply unless it is labeled and offered for sale as a 34 homeopathic drug, in which case the official title used in the homeopathic 35 pharmacopocia pharmacopeia shall apply.

36 (f) Unless its labeling bears: (1) Adequate directions for use; and (2) 37 such adequate warning against use in those pathological conditions or by 38 children where its use may be dangerous to health, or against unsafe 39 dosage or methods or duration of administration or application, in such 40 manner and form, as are necessary for the protection of users. Where any 41 requirement of <u>elause</u> paragraph (1) of this <u>paragraph</u> subsection, as 42 applied to any drug or device, is not necessary for the protection of the 43 public health, the secretary shall promulgate regulations exempting such

1 drug or device from such requirements. Articles exempted under 2 regulations issued under 21 U.S.C. § 352 (f) may also be exempt.

3 (g) If it purports to be a drug the name of which is recognized in an 4 official compendium, unless it is packaged and labeled as prescribed 5 therein. The method of packing may be modified with the consent of the 6 secretary, or if consent is obtained under the federal act. Whenever a drug 7 is recognized in both the United States-pharmacopoeia pharmocopeia and 8 the homeopathic-pharmacopocia pharmocopeia of the United States, it 9 shall be subject to the requirements of the United States-pharmacopoeia 10 pharmocopeia with respect to the packaging and labeling unless it is labeled and offered for sale as a homeopathic drug, in which case it shall 11 12 be subject to the provisions of the homeopathic pharmacopoeia 13 pharmocopeia of the United States, and not to those of the United States pharmacopoeia pharmocopeia. In the event of inconsistency between the 14 15 requirements of this paragraph subsection and those of paragraph 16 subsection (e) as to the name by which the drug or its ingredients shall be 17 designated, the requirements of paragraph subsection (e) shall prevail.

18 (h) If it has been found by the secretary or under the federal act to be 19 a drug liable to deterioration, unless it is packed in such form and manner-20 and its label bears a statement of such precautions, as the regulations 21 adopted by the secretary require as necessary for the protection of public 22 health. No such regulations shall be established for any drug recognized in 23 an official compendium until the secretary shall have informed the 24 appropriate body charged with the revision of such compendium of the 25 need for such packaging or labeling requirements and such body shall have failed within a reasonable time to prescribe such requirements. 26

(i) (1) If it is a drug and its container is so made, formed, or filled as
to be misleading;-or (2) if it is an imitation of another drug; or (3) if it is
offered for sale under the name of another drug.

30 (j) If it is dangerous to health when used in the dosage, or with the 31 frequency of duration prescribed, recommended, or suggested in the 32 labeling thereof.

33 (k) If it is, or purports to be, or is represented as a drug composed 34 wholly or partly of insulin, unless: (1) It is from a batch with respect to 35 which a certificate or release has been issued pursuant to 21 U.S.C. §  $356_{5}$ ; 36 and (2) such certificate or release is in effect with respect to such drug.

(1) If it is, or purports to be, or is represented as a drug composed wholly or partly of any kind of penicillin, streptomycin, chlortetracycline, chloramphenicol, bacitracin, or any other antibiotic drug, or any derivative thereof, unless: (1) It is from a batch with respect to which a certificate or release has been issued pursuant to 21 U.S.C. §  $357_{7}$ ; and (2) such certificate or release is in effect with respect to such drug. This paragraph shall not apply to any drug or class of drugs exempted by regulations promulgated under 21 U.S.C. § 357 (c) or (d). For the purpose of this subsection the term "antibiotic drug" means any drug intended for use by man containing any quantity of any chemical substance which is produced by a microorganism and which has the capacity to inhibit or destroy microorganisms in dilute solution-(, including the chemically synthesized equivalent of any such substance).

7 (m) If it is a color additive, the intended use of which in or on drugs 8 is for the purpose of coloring only, unless its packaging and labeling are in 9 conformity with such packaging and labeling requirements applicable to 10 such color additive, prescribed under the provisions of K.S.A. 65-667, and 11 *amendments thereto*, or of the federal act.

12 (n) In the case of any prescription drug distributed or offered for sale 13 in this state, unless the manufacturer, packer, or distributor thereof includes in all advertisements and other descriptive printed matter issued 14 15 or caused to be issued by the manufacturer, packer, or distributor with 16 respect to that drug a true statement of: (1) The established name, as 17 defined in subsection (e) (2) of this section;; (2) the formula showing 18 quantitatively each ingredient of such drug to the extent required for labels 19 under 21 U.S.C. § 352 (e); and (3) such other information in brief 20 summary relating to side effects, contraindications, and effectiveness as 21 shall be required in regulations issued under the federal act.

(o) If a trademark, trade name or other identifying mark, imprint or
 device of another or any likeness of the foregoing has been placed thereon
 or upon its container with intent to defraud.

(p) Drugs and devices which are, in accordance with the practice of the trade, to be processed, labeled or repacked in substantial quantities at establishments other than those where originally processed or packed shall be exempt from any labeling or packaging requirements of this act if such drugs and devices are being delivered, manufactured, processed, labeled, repacked or otherwise held in compliance with regulations issued by the secretary or under the federal act.

32 (q) A drug intended for use by man humans which (A): (1) Is a habit-33 forming drug to which K.S.A. 65-668, and amendments thereto, applies; 34 or (B) (2) because of its toxicity or other potentiality for harmful effect, or 35 the method of its use, or the collateral measures necessary to its use, is not 36 safe for use except under the supervision of a practitioner licensed by law 37 to administer such drug; or (C) (3) is limited by an approved application 38 under 21 U.S.C. § 355 or K.S.A. 65-669a, and amendments thereto, to use 39 under the professional supervision of a practitioner licensed by law to 40 administer such drug, shall be dispensed only-(i): (A) Upon a written 41 prescription of a practitioner licensed by law to administer such drug or 42 upon the written prescription of a mid-level practitioner as defined in 43 subsection (ii) of K.S.A. 65-1626, and amendments thereto, or (ii); (B)

1 upon an oral prescription of such practitioner or mid-level practitioner 2 which is reduced promptly to writing and filed by the pharmacist;; or (iii) (C) by refilling, any such written or oral prescription if such refilling is 3 4 authorized by the prescriber either in the original prescription or by oral 5 order which is reduced promptly to writing and filed by the pharmacist. 6 The act of dispensing a drug contrary to the provisions of this paragraph 7 shall be deemed to be an act which results in a drug being misbranded 8 while held for sale

9 (r) Any drug dispensed by filling or refilling a written or oral 10 prescription of a practitioner licensed by law to administer such drug or by filling or refilling a written or oral prescription of a mid-level practitioner 11 12 as defined in-subsection (ii) of K.S.A. 65-1626, and amendments thereto, shall be exempt from the requirements of this section, except subsections 13 (a), (i) (2) and (3), (k), and (l), and the packaging requirements of 14 15 subsections (g) and (h), if the drug bears a label containing the name and 16 address of the dispenser, the serial number and date of the prescription or 17 of its filling, the name of the prescriber and, if stated in the prescription, 18 the name of the patient, and the directions for use and cautionary 19 statements, if any, contained in such prescription. This exemption shall not 20 apply to any drug dispensed in the course of the conduct of a business of 21 dispensing drugs pursuant to diagnosis by mail, or to a drug dispensed in 22 violation of paragraph subsection (q) of this section.

23 (s) The secretary may, by regulation, remove drugs subject to 24 subsection (d) of this section and K.S.A. 65-669a, and amendments 25 *thereto*, from the requirements of paragraph subsection (q) of this section 26 when such requirements are not necessary for the protection of the public 27 health. Drugs removed from the prescription requirements of the federal 28 act by regulations issued thereunder may also, by regulations issued by the secretary, be removed from the requirements of paragraph subsection (q) 29 30 of this section.

31 (t) A drug which is subject to paragraph subsection (g) of this section 32 shall be deemed to be misbranded if at any time prior to dispensing its label fails to bear the statement "caution: federal law prohibits dispensing 33 34 without prescription," or "caution: state law prohibits dispensing without 35 prescription." A drug to which paragraph subsection (q) of this section 36 does not apply shall be deemed to be misbranded if at any time prior to 37 dispensing its label bears the caution statement quoted in the preceding 38 sentence.

(u) Nothing in this section shall be construed to relieve any person
from any requirement prescribed by or under authority of law with respect
to drugs now included or which may hereafter be included within the
classifications of narcotic drugs or marijuana as defined in the applicable
federal and state laws relating to narcotic drugs and marijuana.

1 Sec. 19. K.S.A. 65-1660 is hereby amended to read as follows: 65-2 1660. (a) Except as otherwise provided in this section, the provisions of 3 the pharmacy act of the state of Kansas shall not apply to dialysates, 4 devices or drugs which are designated by the board for the purposes of this 5 section relating to treatment of a person with chronic kidney failure 6 receiving dialysis and which are prescribed or ordered by a physician or a 7 mid-level practitioner for administration or delivery to a person with 8 chronic kidney failure if:

9 (1) The wholesale distributor is registered with the board and 10 lawfully holds the drug or device; and

(2) the wholesale distributor: (A) Delivers the drug or device to: (i) A person with chronic kidney failure for self-administration at the person's home or specified address; (ii) a physician for administration or delivery to a person with chronic kidney failure; or (iii) a medicare approved renal dialysis facility for administering or delivering to a person with chronic kidney failure; and (B) has sufficient and qualified supervision to adequately protect the public health.

(b) The wholesale distributor pursuant to subsection (a) shall be
supervised by a pharmacist consultant pursuant to rules and regulations
adopted by the board.

(c) The board shall adopt such rules or regulations as are necessary to
 effectuate the provisions of this section.

(d) As used in this section, "physician" means a person licensed to
practice medicine and surgery; "mid-level practitioner" means mid-level
practitioner as such term is defined in subsection (ii) of K.S.A. 65-1626,
and amendments thereto.

(e) This section shall be part of and supplemental to the pharmacy actof the state of Kansas.

29 Sec. 20. K.S.A. 2015 Supp. 65-1669 is hereby amended to read as 30 follows: 65-1669. As used in the utilization of unused medications act:

(a) "Adult care home" has the same meaning as such term is definedin K.S.A. 39-923, and amendments thereto.

(b) "Community mental health center" has the same meaning as such term is defined in K.S.A. 75-3307c, and amendments thereto.

(c) "Donating entities" means adult care homes, mail service
 pharmacies, institutional drug rooms and medical care facilities who elect
 to participate in the program.

(d) "Drug" has the same meaning as such term is defined in K.S.A.
65-1626, and amendments thereto.

40 (e) "Federally qualified health center" means a center which meets 41 the requirements for federal funding under 42 U.S.C. § 1396d(1) of the 42 public health service act, and amendments thereto, and which has been 43 designated as a "federally qualified health center" by the federal 1 government.

2 (f) "Indigent health care clinic" has the same meaning as such term is 3 defined in K.S.A. 75-6102, and amendments thereto.

4 5

(g) "Institutional drug room" has the meaning as such term is defined in K.S.A. 65-1626(bb), and amendments thereto.

6 (h) "Mail service pharmacy" means a licensed Kansas pharmacy that 7 ships, mails or delivers by any lawful means a lawfully dispensed 8 medication in tamper-resistant packaging to residents of this state or 9 another state.

"Medical care facility" has the same meaning as such term is 10 (i) defined in K.S.A. 65-425, and amendments thereto. 11

12 "Medically indigent" has the same meaning as such term is (i) defined in K.S.A. 75-6102, and amendments thereto. 13

14 (k) "Medication" means a prescription drug or drug as defined by this 15 section.

16 "Mid-level practitioner" has the same meaning as such term is (1)17 defined in K.S.A. 65-1626, and amendments thereto.

18 (m) "Practitioner" has the same meaning as such term is defined in 19 K.S.A. 65-1626, and amendments thereto.

(n) "Prescription drug" means a drug which may be dispensed only 20 21 upon prescription of a practitioner or mid-level practitioner authorized by 22 law and which is approved for safety and effectiveness as a prescription 23 drug under section 505 or 507 of the federal food, drug and cosmetic act, 52 Stat. 1040 (1938), 21 U.S.C.A. § 301. 24

(o) "Oualifying center or clinic" means an indigent health care clinic, 25 26 federally qualified health center or community mental health center.

27 (p) "Samples of medications or injectables" means a unit of drug that 28 is not intended to be sold and is intended to promote the sale of the drug.

29 Sec. 21. K.S.A. 2015 Supp. 65-2837a is hereby amended to read as follows: 65-2837a. (a) It shall be unlawful for any person licensed to 30 31 practice medicine and surgery to prescribe, order, dispense, administer, 32 sell, supply or give or for a mid-level practitioner as defined in subsection 33 (ii) of K.S.A. 65-1626, and amendments thereto, to prescribe, administer, 34 supply or give any amphetamine or sympathomimetic amine designated in 35 schedule II, III or IV under the uniform controlled substances act, except 36 as provided in this section. Failure to comply with this section by a 37 licensee shall constitute unprofessional conduct under K.S.A. 65-2837, 38 and amendments thereto.

39 (b) When any licensee prescribes, orders, dispenses, administers, 40 sells, supplies or gives or when any mid-level practitioner as defined in 41 subsection (ii) of K.S.A. 65-1626, and amendments thereto, prescribes, 42 administers, sells, supplies or gives any amphetamine or sympathomimetic 43 amine designated in schedule II, III or IV under the uniform controlled

51

1 substances act, the patient's medical record shall adequately document the 2 purpose for which the drug is being given. Such purpose shall be restricted

3 to one or more of the following:4 (1) The treatment of narcolepsy.

4 5

(2) The treatment of drug-induced brain dysfunction.

(3) The treatment of hyperkinesis.

6 7

(4) The differential diagnostic psychiatric evaluation of depression.

8 (5) The treatment of depression shown by adequate medical records9 and documentation to be unresponsive to other forms of treatment.

10 (6) The clinical investigation of the effects of such drugs or 11 compounds, in which case, before the investigation is begun, the licensee 12 shall, in addition to other requirements of applicable laws, apply for and 13 obtain approval of the investigation from the board of healing arts.

14 (7) The treatment of obesity with controlled substances, as may be 15 defined by rules and regulations adopted by the board of healing arts.

16 (8) The treatment of any other disorder or disease for which such 17 drugs or compounds have been found to be safe and effective by 18 competent scientific research which findings have been generally accepted 19 by the scientific community, in which case, the licensee before prescribing, 20 ordering, dispensing, administering, selling, supplying or giving the drug 21 or compound for a particular condition, or the licensee before authorizing 22 a mid-level practitioner to prescribe the drug or compound for a particular 23 condition, shall obtain a determination from the board of healing arts that 24 the drug or compound can be used for that particular condition.

Sec. 22. K.S.A. 2015 Supp. 65-4202 is hereby amended to read as follows: 65-4202. As used in this act: (a) "Board" means the state board of nursing.

(b) The "practice of mental health technology" means the
performance, under the direction of a physician licensed to practice
medicine and surgery or registered professional nurse, of services in caring
for and treatment of the mentally ill, emotionally disturbed, or people with
intellectual disability for compensation or personal profit, which services:

(1) Involve responsible nursing and therapeutic procedures for
 patients with mental illness or intellectual disability requiring interpersonal
 and technical skills in the observations and recognition of symptoms and
 reactions of such patients, the accurate recording of such symptoms and
 reactions and the carrying out of treatments and medications as prescribed
 by a licensed physician or a mid-level practitioner as defined in subsection
 (ii) of K.S.A. 65-1626, and amendments thereto; and

40 (2) require an application of techniques and procedures that involve
41 understanding of cause and effect and the safeguarding of life and health
42 of the patient and others; and

43 (3) require the performance of duties that are necessary to facilitate

rehabilitation of the patient or are necessary in the physical, therapeutic
 and psychiatric care of the patient and require close work with persons
 licensed to practice medicine and surgery, psychiatrists, psychologists,
 rehabilitation therapists, social workers, registered nurses, and other
 professional personnel.

6 (c) A "licensed mental health technician" means a person who 7 lawfully practices mental health technology as defined in this act.

8 (d) An "approved course in mental health technology" means a 9 program of training and study including a basic curriculum which shall be 10 prescribed and approved by the board in accordance with the standards 11 prescribed herein, the successful completion of which shall be required 12 before licensure as a mental health technician, except as hereinafter 13 provided.

14 Sec. 23. K.S.A. 65-7007 is hereby amended to read as follows: 65-15 7007. (a) Each regulated chemical distributor and retailer shall submit to 16 the bureau:

(1) Any regulated transaction involving an extraordinary quantity of a
regulated chemical, an uncommon method of payment or delivery, or any
other circumstance that may indicate that the regulated chemical will be
used in violation of this act.

(2) Any proposed regulated transaction with a person whose
 description or other identifying characteristic the bureau has previously
 furnished to the regulated chemical distributor or retailer.

(3) Any unusual or excessive loss or disappearance of a regulated
chemical under the control of the regulated chemical distributor or retailer.
The regulated person responsible for reporting a loss in-transit is the
distributor.

28 (b) Each report submitted pursuant to subsection (a), whenever 29 possible shall be made orally to the bureau at the earliest practicable opportunity after the regulated chemical distributor or retailer becomes 30 31 aware of the circumstances involved and as much in advance of the 32 conclusion of the transaction as possible. Written reports of these 33 transactions shall subsequently be filed within 15 days after the regulated 34 chemical distributor or retailer becomes aware of the circumstances of the 35 event. A transaction may not be completed with a person whose 36 description or identifying characteristics have previously been furnished to 37 the regulated distributor by the bureau unless the transaction is approved 38 by the bureau.

39 (c) T

(c) This section shall not apply to any of the following:

40 (1) Any pharmacist, pharmacy or other authorized person who sells 41 or furnishes a substance listed in-subsection (1) of K.S.A. 65-7003(1), and 42 amendments thereto, upon the prescription or order of a practitioner as 43 defined under-subsection (x) of K.S.A. 65-1626, and amendments thereto; (2) any practitioner as defined under-subsection (x) of K.S.A. 65 1626, and amendments thereto, who administers, dispenses or furnishes a
 substance listed in-subsection (1) of K.S.A. 65-7003(1), and amendments
 thereto, to such patients within the scope of a practitioner's professional
 practice. Such administration or dispensing shall be in the patient record;

15

16

6 (3) anany sale, transfer, furnishing or receipt of any drug which 7 contains any substance listed in-subsection (1) of K.S.A. 65-7003(1), and 8 amendments thereto, and which is lawfully sold, transferred or furnished 9 over-the-counter without a prescription pursuant to the federal food, drug 10 and cosmetic act or regulations adopted thereunder; and

(4) a regulated chemical retailer who only sells or distributes
regulated chemicals that are nonprescription, over-the-counter medicines
with less than three grams of base ingredient in the package in the
following manner:

(A) Blister packs of not more than two dosage units per blister;

(B) liquid cold or cough medicines;

17 (C) liquid cold or cough gel capsules; and

18 (D) nasal drops or sprays.

Sec. 24. K.S.A. 65-669, 65-1633, 65-1635, 65-1648, 65-1660 and 657007 and K.S.A. 2015 Supp. 65-1626, 65-1627, 65-1636, 65-1637, 651637b, 65-1642, 65-1643, 65-1645, 65-1651a, 65-1655, 65-1663, 65-1669,
65-1676, 65-2837a and 65-4202 are hereby repealed.

Sec. 25. This act shall take effect and be in force from and after itspublication in the statute book.